disease,drug,phase,status,target,num_ev_strings
breast carcinoma,DOXORUBICIN,2,Completed,TOP2A,73
lymphoma,ETOPOSIDE,2,Completed,TOP2A,65
lymphoma,DOXORUBICIN,2,Completed,TOP2A,54
breast carcinoma,DOXORUBICIN,3,Completed,TOP2A,33
lymphoma,DOXORUBICIN,3,Completed,TOP2A,31
leukemia,ETOPOSIDE,2,Completed,TOP2A,29
multiple myeloma,DOXORUBICIN,2,Completed,TOP2A,20
lymphoma,ETOPOSIDE,3,Completed,TOP2A,20
leukemia,DAUNORUBICIN,2,Completed,TOP2A,19
breast carcinoma,DOXORUBICIN,2,Unknown status,TOP2A,19
breast carcinoma,DOXORUBICIN,2,Terminated,TOP2A,17
breast carcinoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,16
leukemia,DAUNORUBICIN,3,Completed,TOP2A,16
breast carcinoma,DOXORUBICIN,2,Recruiting,TOP2A,16
breast carcinoma,DOXORUBICIN,1,Completed,TOP2A,16
neoplasm,DOXORUBICIN,1,Completed,TOP2A,15
leukemia,ETOPOSIDE,1,Completed,TOP2A,14
sarcoma,DOXORUBICIN,2,Completed,TOP2A,14
lung carcinoma,ETOPOSIDE,2,Completed,TOP2A,14
breast carcinoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,14
lymphoma,DOXORUBICIN,1,Completed,TOP2A,14
sarcoma,DOXORUBICIN,1,Completed,TOP2A,14
neuroblastoma,ETOPOSIDE,2,Completed,TOP2A,14
lymphoma,ETOPOSIDE,2,Unknown status,TOP2A,13
lymphoma,ETOPOSIDE,1,Completed,TOP2A,13
diffuse large B-cell lymphoma,DOXORUBICIN,2,Completed,TOP2A,13
leukemia,ETOPOSIDE,3,Completed,TOP2A,13
lymphoma,DOXORUBICIN,2,Unknown status,TOP2A,13
lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,13
ovarian carcinoma,DOXORUBICIN,2,Completed,TOP2A,12
leukemia,MITOXANTRONE,2,Completed,TOP2A,12
breast neoplasm,DOXORUBICIN,2,Completed,TOP2A,12
acute myeloid leukemia,DAUNORUBICIN,3,Completed,TOP2A,12
leukemia,DOXORUBICIN,3,Completed,TOP2A,12
acute myeloid leukemia,DAUNORUBICIN,1,Recruiting,TOP2A,11
acute myeloid leukemia,MITOXANTRONE,1,Completed,TOP2A,11
acute myeloid leukemia,IDARUBICIN,2,Completed,TOP2A,11
lymphoma,ETOPOSIDE,3,Unknown status,TOP2A,11
Hodgkins lymphoma,DOXORUBICIN,2,Recruiting,TOP2A,11
neuroblastoma,DOXORUBICIN,2,Completed,TOP2A,11
lung carcinoma,ETOPOSIDE,3,Completed,TOP2A,11
sarcoma,DOXORUBICIN,3,Completed,TOP2A,10
leukemia,IDARUBICIN,2,Completed,TOP2A,10
hepatocellular carcinoma,DOXORUBICIN,2,Completed,TOP2A,10
small cell lung carcinoma,ETOPOSIDE,2,Completed,TOP2A,10
small cell lung carcinoma,ETOPOSIDE,1,Completed,TOP2A,10
lymphoma,DOXORUBICIN,3,Unknown status,TOP2A,10
lymphoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,10
acute myeloid leukemia,ETOPOSIDE,1,Completed,TOP2A,10
multiple myeloma,DOXORUBICIN,3,Completed,TOP2A,10
lymphoma,DOXORUBICIN,2,Terminated,TOP2A,9
acute myeloid leukemia,IDARUBICIN,1,Recruiting,TOP2A,9
acute myeloid leukemia,IDARUBICIN,1,Completed,TOP2A,9
breast carcinoma,DOXORUBICIN,3,Unknown status,TOP2A,9
leukemia,DOXORUBICIN,2,Completed,TOP2A,9
prostate carcinoma,MITOXANTRONE,2,Completed,TOP2A,9
small cell lung carcinoma,ETOPOSIDE,1,Terminated,TOP2A,8
central nervous system cancer,ETOPOSIDE,2,Completed,TOP2A,8
leukemia,DAUNORUBICIN,1,Completed,TOP2A,8
lymphoma,MITOXANTRONE,3,Completed,TOP2A,8
neuroblastoma,ETOPOSIDE,3,Completed,TOP2A,8
multiple myeloma,ETOPOSIDE,2,Completed,TOP2A,8
diffuse large B-cell lymphoma,ETOPOSIDE,2,Recruiting,TOP2A,8
lymphoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,8
leukemia,ETOPOSIDE,3,Unknown status,TOP2A,8
non-Hodgkins lymphoma,ETOPOSIDE,2,Terminated,TOP2A,8
non-Hodgkins lymphoma,ETOPOSIDE,2,Completed,TOP2A,8
hepatocellular carcinoma,DOXORUBICIN,2,Unknown status,TOP2A,8
acute myeloid leukemia,MITOXANTRONE,2,Recruiting,TOP2A,8
ovarian carcinoma,DOXORUBICIN,1,Completed,TOP2A,8
acute myeloid leukemia,DAUNORUBICIN,1,Completed,TOP2A,8
acute myeloid leukemia,DAUNORUBICIN,2,"Active, not recruiting",TOP2A,8
lung carcinoma,ETOPOSIDE,1,Completed,TOP2A,8
leukemia,IDARUBICIN,3,Completed,TOP2A,7
sarcoma,DOXORUBICIN,2,Terminated,TOP2A,7
small cell lung carcinoma,ETOPOSIDE,3,Completed,TOP2A,7
Hodgkins lymphoma,DOXORUBICIN,2,Completed,TOP2A,7
diffuse large B-cell lymphoma,ETOPOSIDE,2,Completed,TOP2A,7
acute myeloid leukemia,IDARUBICIN,1,"Active, not recruiting",TOP2A,7
neuroblastoma,DOXORUBICIN,3,Completed,TOP2A,7
diffuse large B-cell lymphoma,DOXORUBICIN,3,Recruiting,TOP2A,7
acute lymphoblastic leukemia,DOXORUBICIN,2,Recruiting,TOP2A,7
diffuse large B-cell lymphoma,DOXORUBICIN,2,Recruiting,TOP2A,7
Hodgkins lymphoma,DOXORUBICIN,3,Completed,TOP2A,7
leukemia,MITOXANTRONE,1,Completed,TOP2A,7
cancer,DOXORUBICIN,1,Completed,TOP2A,7
acute lymphoblastic leukemia,DAUNORUBICIN,4,Completed,TOP2A,7
acute myeloid leukemia,MITOXANTRONE,1,"Active, not recruiting",TOP2A,7
ovarian carcinoma,DOXORUBICIN,1,Terminated,TOP2A,7
leukemia,IDARUBICIN,1,Completed,TOP2A,7
diffuse large B-cell lymphoma,DOXORUBICIN,1,Recruiting,TOP2A,6
acute myeloid leukemia,MITOXANTRONE,3,Recruiting,TOP2A,6
hepatocellular carcinoma,DOXORUBICIN,1,Completed,TOP2A,6
small cell lung carcinoma,ETOPOSIDE,3,"Active, not recruiting",TOP2A,6
ovarian carcinoma,DOXORUBICIN,3,Completed,TOP2A,6
ovarian neoplasm,DOXORUBICIN,2,Completed,TOP2A,6
acute myeloid leukemia,DAUNORUBICIN,2,Recruiting,TOP2A,6
small cell lung carcinoma,ETOPOSIDE,2,Recruiting,TOP2A,6
acute myeloid leukemia,ETOPOSIDE,3,Completed,TOP2A,6
non-Hodgkins lymphoma,DOXORUBICIN,2,Terminated,TOP2A,6
acute myeloid leukemia,DAUNORUBICIN,3,Recruiting,TOP2A,6
acute myeloid leukemia,IDARUBICIN,2,Recruiting,TOP2A,6
prostate carcinoma,ETOPOSIDE,2,Completed,TOP2A,6
diffuse large B-cell lymphoma,DOXORUBICIN,3,Completed,TOP2A,6
acute myeloid leukemia,ETOPOSIDE,2,Recruiting,TOP2A,6
leukemia,IDARUBICIN,3,Unknown status,TOP2A,6
Hodgkins lymphoma,ETOPOSIDE,1,Completed,TOP2A,6
Hodgkins lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,6
leukemia,MITOXANTRONE,3,Completed,TOP2A,6
Hodgkins lymphoma,ETOPOSIDE,2,Recruiting,TOP2A,6
diffuse large B-cell lymphoma,DOXORUBICIN,2,Terminated,TOP2A,5
neuroblastoma,ETOPOSIDE,1,Completed,TOP2A,5
diffuse large B-cell lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,5
breast carcinoma,DOXORUBICIN,1,Terminated,TOP2A,5
lung carcinoma,ETOPOSIDE,3,Unknown status,TOP2A,5
breast carcinoma,DOXORUBICIN,2,Withdrawn,TOP2A,5
acute lymphoblastic leukemia,ETOPOSIDE,3,Recruiting,TOP2A,5
breast carcinoma,DOXORUBICIN,3,Recruiting,TOP2A,5
prostate carcinoma,DOXORUBICIN,1,Completed,TOP2A,5
Hodgkins lymphoma,ETOPOSIDE,2,Completed,TOP2A,5
breast carcinoma,ETOPOSIDE,2,Completed,TOP2A,5
acute lymphoblastic leukemia,ETOPOSIDE,2,Completed,TOP2A,5
acute lymphoblastic leukemia,DOXORUBICIN,4,Completed,TOP2A,5
non-small cell lung carcinoma,ETOPOSIDE,1,Terminated,TOP2A,5
acute lymphoblastic leukemia,DOXORUBICIN,2,Completed,TOP2A,5
small cell lung carcinoma,ETOPOSIDE,1,"Active, not recruiting",TOP2A,5
myelodysplastic syndrome,ETOPOSIDE,1,Completed,TOP2A,5
acute myeloid leukemia,DAUNORUBICIN,1,"Active, not recruiting",TOP2A,5
leukemia,DAUNORUBICIN,3,Unknown status,TOP2A,5
lymphoma,MITOXANTRONE,2,Completed,TOP2A,5
multiple myeloma,DOXORUBICIN,1,Completed,TOP2A,5
lymphoma,ETOPOSIDE,2,Recruiting,TOP2A,5
diffuse large B-cell lymphoma,ETOPOSIDE,2,Terminated,TOP2A,5
neoplasm,ETOPOSIDE,1,Completed,TOP2A,5
prostate carcinoma,DOXORUBICIN,2,Completed,TOP2A,5
lymphoma,DOXORUBICIN,3,Terminated,TOP2A,5
bladder carcinoma,DOXORUBICIN,2,Completed,TOP2A,5
diffuse large B-cell lymphoma,ETOPOSIDE,1,Completed,TOP2A,5
lymphoma,DAUNORUBICIN,3,Unknown status,TOP2A,4
breast neoplasm,DOXORUBICIN,3,Completed,TOP2A,4
acute myeloid leukemia,ETOPOSIDE,3,"Active, not recruiting",TOP2A,4
acute myeloid leukemia,ETOPOSIDE,1,"Active, not recruiting",TOP2A,4
acute myeloid leukemia,MITOXANTRONE,3,"Active, not recruiting",TOP2A,4
acute myeloid leukemia,MITOXANTRONE,3,Completed,TOP2A,4
leukemia,MITOXANTRONE,3,Unknown status,TOP2A,4
lymphoma,ETOPOSIDE,3,Terminated,TOP2A,4
acute myeloid leukemia,IDARUBICIN,2,"Active, not recruiting",TOP2A,4
small cell lung carcinoma,ETOPOSIDE,3,Unknown status,TOP2A,4
acute lymphoblastic leukemia,ETOPOSIDE,2,Recruiting,TOP2A,4
lymphoma,ETOPOSIDE,2,Withdrawn,TOP2A,4
sarcoma,DOXORUBICIN,2,Recruiting,TOP2A,4
lymphoma,DOXORUBICIN,2,Recruiting,TOP2A,4
bladder carcinoma,DOXORUBICIN,3,Completed,TOP2A,4
peritoneal neoplasm,DOXORUBICIN,1,Completed,TOP2A,4
lymphoma,DAUNORUBICIN,2,Completed,TOP2A,4
lung carcinoma,ETOPOSIDE,2,Unknown status,TOP2A,4
acute lymphoblastic leukemia,DOXORUBICIN,3,Recruiting,TOP2A,4
multiple myeloma,DOXORUBICIN,2,Terminated,TOP2A,4
Hodgkins lymphoma,DOXORUBICIN,2,Unknown status,TOP2A,4
breast carcinoma,DOXORUBICIN,1,Withdrawn,TOP2A,4
acute myeloid leukemia,DAUNORUBICIN,2,Completed,TOP2A,4
multiple myeloma,DOXORUBICIN,3,Unknown status,TOP2A,4
ovarian carcinoma,DOXORUBICIN,2,Terminated,TOP2A,4
lymphoma,DOXORUBICIN,2,Withdrawn,TOP2A,4
unspecified peripheral T-cell lymphoma,DOXORUBICIN,2,Completed,TOP2A,4
breast carcinoma,DOXORUBICIN,3,Terminated,TOP2A,4
ovarian carcinoma,DOXORUBICIN,1,Recruiting,TOP2A,4
acute myeloid leukemia,ETOPOSIDE,2,Completed,TOP2A,4
sarcoma,ETOPOSIDE,2,Completed,TOP2A,4
diffuse large B-cell lymphoma,DOXORUBICIN,1,Completed,TOP2A,4
Mantle cell lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,4
"Lymphoma, AIDS-Related",ETOPOSIDE,2,Completed,TOP2A,4
leukemia,DAUNORUBICIN,2,Unknown status,TOP2A,4
Mantle cell lymphoma,DOXORUBICIN,2,Completed,TOP2A,4
diffuse large B-cell lymphoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,4
endometrial neoplasm,DOXORUBICIN,2,Completed,TOP2A,4
diffuse large B-cell lymphoma,ETOPOSIDE,1,Withdrawn,TOP2A,4
acute lymphoblastic leukemia,DAUNORUBICIN,2,Completed,TOP2A,4
small cell lung carcinoma,AMRUBICIN,2,Completed,TOP2A,4
leukemia,DOXORUBICIN,3,"Active, not recruiting",TOP2A,4
diffuse large B-cell lymphoma,ETOPOSIDE,1,Recruiting,TOP2A,4
leukemia,ETOPOSIDE,2,Recruiting,TOP2A,4
acute lymphoblastic leukemia,DAUNORUBICIN,3,Recruiting,TOP2A,4
non-Hodgkins lymphoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,4
acute lymphoblastic leukemia,DOXORUBICIN,1,Completed,TOP2A,4
non-small cell lung carcinoma,ETOPOSIDE,2,Completed,TOP2A,4
leukemia,DOXORUBICIN,2,Recruiting,TOP2A,4
soft tissue sarcoma,DOXORUBICIN,1,Completed,TOP2A,4
leukemia,IDARUBICIN,2,Unknown status,TOP2A,4
non-Hodgkins lymphoma,MITOXANTRONE,2,Completed,TOP2A,4
neoplasm,ALDOXORUBICIN,1,Completed,TOP2A,4
leukemia,IDARUBICIN,2,"Active, not recruiting",TOP2A,4
diffuse large B-cell lymphoma,DOXORUBICIN,2,Unknown status,TOP2A,4
"Lymphoma, AIDS-Related",DOXORUBICIN,2,Completed,TOP2A,4
multiple myeloma,DOXORUBICIN,2,Unknown status,TOP2A,3
leukemia,DAUNORUBICIN,2,Recruiting,TOP2A,3
leukemia,DAUNORUBICIN,3,"Active, not recruiting",TOP2A,3
acute myeloid leukemia,MITOXANTRONE,1,Recruiting,TOP2A,3
acute myeloid leukemia,MITOXANTRONE,1,Terminated,TOP2A,3
acute myeloid leukemia,MITOXANTRONE,2,Completed,TOP2A,3
leukemia,DOXORUBICIN,2,"Active, not recruiting",TOP2A,3
myelodysplastic syndrome,IDARUBICIN,2,Completed,TOP2A,3
prostate carcinoma,DOXORUBICIN,2,Terminated,TOP2A,3
lymphoma,ETOPOSIDE PHOSPHATE,2,Completed,TOP2A,3
hepatocellular carcinoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,3
lymphoma,MITOXANTRONE,3,Unknown status,TOP2A,3
neoplasm of mature B-cells,DOXORUBICIN,2,Completed,TOP2A,3
hepatocellular carcinoma,DOXORUBICIN,3,Completed,TOP2A,3
hepatocellular carcinoma,DOXORUBICIN,3,Unknown status,TOP2A,3
prostate carcinoma,MITOXANTRONE,1,Completed,TOP2A,3
multiple myeloma,DOXORUBICIN,1,Terminated,TOP2A,3
germ cell tumor,ETOPOSIDE,2,"Active, not recruiting",TOP2A,3
acute myeloid leukemia,IDARUBICIN,3,Completed,TOP2A,3
acute myeloid leukemia,IDARUBICIN,1,Withdrawn,TOP2A,3
endometrial neoplasm,DOXORUBICIN,3,Completed,TOP2A,3
lymphoma,ETOPOSIDE,3,"Active, not recruiting",TOP2A,3
lymphoma,ETOPOSIDE,2,Terminated,TOP2A,3
multiple myeloma,DOXORUBICIN,2,Withdrawn,TOP2A,3
acute myeloid leukemia,IDARUBICIN,2,Unknown status,TOP2A,3
lymphoma,ETOPOSIDE,1,"Active, not recruiting",TOP2A,3
neuroblastoma,DOXORUBICIN,1,Completed,TOP2A,3
bladder carcinoma,DOXORUBICIN,2,Terminated,TOP2A,3
diffuse large B-cell lymphoma,DOXORUBICIN,3,Unknown status,TOP2A,3
acute myeloid leukemia,VOSAROXIN,2,Recruiting,TOP2A,3
non-small cell lung carcinoma,ETOPOSIDE,3,Completed,TOP2A,3
leukemia,MITOXANTRONE,2,Unknown status,TOP2A,3
central nervous system cancer,ETOPOSIDE,1,Completed,TOP2A,3
breast carcinoma,MITOXANTRONE,3,Completed,TOP2A,3
breast carcinoma,ETOPOSIDE,2,Terminated,TOP2A,3
non-Hodgkins lymphoma,ETOPOSIDE,2,Recruiting,TOP2A,3
leukemia,ETOPOSIDE,2,Unknown status,TOP2A,3
lung carcinoma,ETOPOSIDE,2,Terminated,TOP2A,3
non-Hodgkins lymphoma,DOXORUBICIN,2,Completed,TOP2A,3
chronic lymphocytic leukemia,ETOPOSIDE,2,Completed,TOP2A,3
non-Hodgkins lymphoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,3
myelodysplastic syndrome,DAUNORUBICIN,3,Completed,TOP2A,3
neuroblastoma,ETOPOSIDE,3,Unknown status,TOP2A,3
lymphoid leukemia,DOXORUBICIN,2,Recruiting,TOP2A,3
multiple myeloma,ETOPOSIDE,2,Terminated,TOP2A,3
breast carcinoma,DOXORUBICIN,2,Not yet recruiting,TOP2A,3
multiple myeloma,ETOPOSIDE,2,Recruiting,TOP2A,3
neuroblastoma,ETOPOSIDE,2,Recruiting,TOP2A,3
breast carcinoma,DOXORUBICIN,1,Unknown status,TOP2A,3
leukemia,ETOPOSIDE,1,Recruiting,TOP2A,3
multiple myeloma,ETOPOSIDE,1,Completed,TOP2A,3
ovarian carcinoma,DOXORUBICIN,2,Unknown status,TOP2A,3
brain neoplasm,ETOPOSIDE,1,Completed,TOP2A,3
ovarian carcinoma,DOXORUBICIN,3,Unknown status,TOP2A,3
bladder carcinoma,VALRUBICIN,2,Completed,TOP2A,3
osteosarcoma,DOXORUBICIN,2,Completed,TOP2A,3
bladder carcinoma,DOXORUBICIN,1,Completed,TOP2A,3
diffuse large B-cell lymphoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,3
peritoneal neoplasm,DOXORUBICIN,1,Terminated,TOP2A,3
hepatocellular carcinoma,DOXORUBICIN,2,Terminated,TOP2A,3
leukemia,DOXORUBICIN,3,Unknown status,TOP2A,3
small cell lung carcinoma,ETOPOSIDE,2,Not yet recruiting,TOP2A,3
Fallopian Tube Carcinoma,DOXORUBICIN,1,Terminated,TOP2A,3
Hodgkins lymphoma,DOXORUBICIN,1,Completed,TOP2A,3
Hodgkins lymphoma,DOXORUBICIN,1,Recruiting,TOP2A,3
Hodgkins lymphoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,3
Hodgkins lymphoma,DOXORUBICIN,3,Recruiting,TOP2A,3
transitional cell carcinoma of kidney,DOXORUBICIN,1,Completed,TOP2A,3
Hodgkins lymphoma,ETOPOSIDE,1,Recruiting,TOP2A,3
Hodgkins lymphoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,3
soft tissue sarcoma,DOXORUBICIN,2,Recruiting,TOP2A,3
Mantle cell lymphoma,ETOPOSIDE,2,Recruiting,TOP2A,3
acute myeloid leukemia,ETOPOSIDE,1,Terminated,TOP2A,3
small cell lung carcinoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,3
acute lymphoblastic leukemia,ETOPOSIDE,4,Completed,TOP2A,3
acute lymphoblastic leukemia,ETOPOSIDE,3,Unknown status,TOP2A,3
sarcoma,DOXORUBICIN,2,Unknown status,TOP2A,3
sarcoma,ETOPOSIDE,3,Unknown status,TOP2A,3
sarcoma,ETOPOSIDE,3,Completed,TOP2A,3
acute lymphoblastic leukemia,ETOPOSIDE,1,Completed,TOP2A,3
acute lymphoblastic leukemia,DAUNORUBICIN,4,Unknown status,TOP2A,3
sarcoma,ETOPOSIDE,1,Completed,TOP2A,3
acute lymphoblastic leukemia,DOXORUBICIN,1,Recruiting,TOP2A,3
acute lymphoblastic leukemia,DOXORUBICIN,1,Terminated,TOP2A,3
acute myeloid leukemia,DAUNORUBICIN,2,Not yet recruiting,TOP2A,3
sarcoma,DOXORUBICIN,3,Unknown status,TOP2A,3
Fallopian Tube Carcinoma,DOXORUBICIN,1,Completed,TOP2A,3
acute myeloid leukemia,DAUNORUBICIN,3,Unknown status,TOP2A,3
acute myeloid leukemia,DAUNORUBICIN,3,"Active, not recruiting",TOP2A,3
Retinoblastoma,ETOPOSIDE,3,"Active, not recruiting",TOP2A,2
diffuse large B-cell lymphoma,ETOPOSIDE,3,Recruiting,TOP2A,2
diffuse large B-cell lymphoma,ETOPOSIDE,3,Completed,TOP2A,2
Retinoblastoma,ETOPOSIDE,2,Completed,TOP2A,2
Retinoblastoma,ETOPOSIDE,2,Recruiting,TOP2A,2
Retinoblastoma,ETOPOSIDE,2,Unknown status,TOP2A,2
neuroblastoma,DOXORUBICIN,2,Recruiting,TOP2A,2
multiple myeloma,DOXORUBICIN,1,Unknown status,TOP2A,2
diffuse large B-cell lymphoma,MITOXANTRONE,2,Recruiting,TOP2A,2
lymphoma,IDARUBICIN,3,Completed,TOP2A,2
Sinonasal Undifferentiated Carcinoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,2
lymphoma,IDARUBICIN,3,Unknown status,TOP2A,2
lymphoma,MITOXANTRONE,1,Unknown status,TOP2A,2
Sinonasal Undifferentiated Carcinoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,2
neuroblastoma,DOXORUBICIN,2,Unknown status,TOP2A,2
diffuse large B-cell lymphoma,MITOXANTRONE,2,Completed,TOP2A,2
neoplasm of mature B-cells,MITOXANTRONE,2,Terminated,TOP2A,2
diffuse large B-cell lymphoma,DOXORUBICIN,3,Terminated,TOP2A,2
neoplasm of mature B-cells,DOXORUBICIN,1,Recruiting,TOP2A,2
hepatocellular carcinoma,DOXORUBICIN,3,Recruiting,TOP2A,2
Primary hemophagocytic lymphohistiocytosis,DOXORUBICIN,3,Recruiting,TOP2A,2
small cell lung carcinoma,ETOPOSIDE,3,Not yet recruiting,TOP2A,2
neoplasm,ETOPOSIDE,4,n/a,TOP2A,2
neoplasm,MITOXANTRONE,1,Completed,TOP2A,2
neoplasm,VOSAROXIN,1,Completed,TOP2A,2
Primary hemophagocytic lymphohistiocytosis,ETOPOSIDE,3,Recruiting,TOP2A,2
neoplasm of mature B-cells,MITOXANTRONE,2,Completed,TOP2A,2
neoplasm of mature B-cells,DOXORUBICIN,2,Recruiting,TOP2A,2
neoplasm of mature B-cells,DOXORUBICIN,3,"Active, not recruiting",TOP2A,2
gastric carcinoma,DOXORUBICIN,2,Completed,TOP2A,2
neoplasm of mature B-cells,DOXORUBICIN,3,Recruiting,TOP2A,2
endometrial neoplasm,DOXORUBICIN,3,Terminated,TOP2A,2
small cell lung carcinoma,ETOPOSIDE,2,Unknown status,TOP2A,2
small cell lung carcinoma,ETOPOSIDE,1,Not yet recruiting,TOP2A,2
Fallopian Tube Carcinoma,DOXORUBICIN,1,Recruiting,TOP2A,2
Nephroblastoma,DOXORUBICIN,3,Completed,TOP2A,2
central nervous system cancer,ETOPOSIDE,3,Unknown status,TOP2A,2
mesothelioma,DOXORUBICIN,2,Unknown status,TOP2A,2
male breast carcinoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,2
non-Hodgkins lymphoma,ETOPOSIDE,2,Unknown status,TOP2A,2
non-Hodgkins lymphoma,ETOPOSIDE,3,Recruiting,TOP2A,2
childhood B acute lymphoblastic leukemia,DOXORUBICIN,3,Completed,TOP2A,2
non-small cell lung carcinoma,ETOPOSIDE,1,Completed,TOP2A,2
central nervous system cancer,ETOPOSIDE,2,Unknown status,TOP2A,2
neuroblastoma,DOXORUBICIN,3,Unknown status,TOP2A,2
medulloblastoma,ETOPOSIDE,3,Completed,TOP2A,2
medulloblastoma,ETOPOSIDE,1,Recruiting,TOP2A,2
acute lymphoblastic leukemia,DOXORUBICIN,2,"Active, not recruiting",TOP2A,2
non-small cell lung carcinoma,ETOPOSIDE,2,Not yet recruiting,TOP2A,2
non-small cell lung carcinoma,ETOPOSIDE,2,Recruiting,TOP2A,2
non-small cell lung carcinoma,ETOPOSIDE,2,Terminated,TOP2A,2
acute lymphoblastic leukemia,DAUNORUBICIN,4,Recruiting,TOP2A,2
non-Hodgkins lymphoma,ETOPOSIDE,1,Recruiting,TOP2A,2
non-Hodgkins lymphoma,ETOPOSIDE,1,Completed,TOP2A,2
non-Hodgkins lymphoma,ETOPOSIDE,1,"Active, not recruiting",TOP2A,2
non-Hodgkins lymphoma,DOXORUBICIN,3,Completed,TOP2A,2
sarcoma,ETOPOSIDE,2,Terminated,TOP2A,2
acute lymphoblastic leukemia,DAUNORUBICIN,3,"Active, not recruiting",TOP2A,2
non-Hodgkins lymphoma,DOXORUBICIN,1,Completed,TOP2A,2
male breast carcinoma,DOXORUBICIN,1,Completed,TOP2A,2
chronic lymphocytic leukemia,MITOXANTRONE,2,Completed,TOP2A,2
Burkitts lymphoma,DOXORUBICIN,2,Completed,TOP2A,2
neuroblastoma,ETOPOSIDE PHOSPHATE,3,Unknown status,TOP2A,2
acute lymphoblastic leukemia,DAUNORUBICIN,1,Recruiting,TOP2A,2
neuroblastoma,ETOPOSIDE,2,Terminated,TOP2A,2
lymphoma,MITOXANTRONE,2,Terminated,TOP2A,2
Burkitts lymphoma,DOXORUBICIN,2,Terminated,TOP2A,2
diffuse large B-cell lymphoma,DOXORUBICIN,1,Withdrawn,TOP2A,2
diffuse large B-cell lymphoma,DOXORUBICIN,3,Not yet recruiting,TOP2A,2
Mantle cell lymphoma,MITOXANTRONE,2,Terminated,TOP2A,2
neoplasm,DOXORUBICIN,2,Recruiting,TOP2A,2
Hodgkins lymphoma,DOXORUBICIN,4,Recruiting,TOP2A,2
Ewing sarcoma,DOXORUBICIN,2,Terminated,TOP2A,2
multiple myeloma,ETOPOSIDE,3,Completed,TOP2A,2
lymphoid leukemia,DOXORUBICIN,2,Completed,TOP2A,2
multiple myeloma,ETOPOSIDE,3,Terminated,TOP2A,2
multiple myeloma,IDARUBICIN,3,Unknown status,TOP2A,2
myelodysplastic syndrome,DAUNORUBICIN,2,Recruiting,TOP2A,2
Hodgkins lymphoma,DOXORUBICIN,4,Unknown status,TOP2A,2
lung carcinoma,AMRUBICIN,3,Completed,TOP2A,2
Hodgkins lymphoma,ETOPOSIDE,1,"Active, not recruiting",TOP2A,2
urethral neoplasm,DOXORUBICIN,2,Completed,TOP2A,2
multiple myeloma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,2
lung carcinoma,ETOPOSIDE,1,Unknown status,TOP2A,2
lung carcinoma,DOXORUBICIN,3,Unknown status,TOP2A,2
lung carcinoma,DOXORUBICIN,3,Completed,TOP2A,2
lymphoid leukemia,ETOPOSIDE,2,Recruiting,TOP2A,2
lymphoma,ETOPOSIDE,1,Unknown status,TOP2A,2
multiple myeloma,ETOPOSIDE,1,Recruiting,TOP2A,2
Hodgkins lymphoma,DOXORUBICIN,2,Terminated,TOP2A,2
lymphoid leukemia,MITOXANTRONE,2,Completed,TOP2A,2
transitional cell carcinoma of kidney,DOXORUBICIN,2,Completed,TOP2A,2
multiple myeloma,DOXORUBICIN,3,Terminated,TOP2A,2
unspecified peripheral T-cell lymphoma,DOXORUBICIN,3,Unknown status,TOP2A,2
multiple myeloma,DOXORUBICIN,2,Recruiting,TOP2A,2
lymphoma,DAUNORUBICIN,3,Completed,TOP2A,2
lymphoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,2
triple-negative breast cancer,DOXORUBICIN,2,"Active, not recruiting",TOP2A,2
lymphoma,DOXORUBICIN,1,Terminated,TOP2A,2
lymphoma,DOXORUBICIN,1,Withdrawn,TOP2A,2
unspecified peripheral T-cell lymphoma,DOXORUBICIN,2,Recruiting,TOP2A,2
Fallopian Tube Carcinoma,DOXORUBICIN,2,Unknown status,TOP2A,2
lymphoma,DOXORUBICIN,3,Recruiting,TOP2A,2
myelodysplastic syndrome,ETOPOSIDE,2,Completed,TOP2A,2
lung carcinoma,AMRUBICIN,1,Completed,TOP2A,2
inflammatory breast carcinoma,DOXORUBICIN,2,Recruiting,TOP2A,2
myelodysplastic syndrome,VOSAROXIN,2,Recruiting,TOP2A,2
myelodysplastic syndrome,VOSAROXIN,1,Completed,TOP2A,2
leukemia,DOXORUBICIN,2,Unknown status,TOP2A,2
non-small cell lung carcinoma,ETOPOSIDE,3,Recruiting,TOP2A,2
Mantle cell lymphoma,DOXORUBICIN,3,Completed,TOP2A,2
Mantle cell lymphoma,DOXORUBICIN,3,Recruiting,TOP2A,2
Mantle cell lymphoma,DOXORUBICIN,3,Unknown status,TOP2A,2
leukemia,DOXORUBICIN,1,Completed,TOP2A,2
myelodysplastic syndrome,ETOPOSIDE,3,Completed,TOP2A,2
Mantle cell lymphoma,ETOPOSIDE,1,Completed,TOP2A,2
Mantle cell lymphoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,2
Burkitts lymphoma,ETOPOSIDE,2,Terminated,TOP2A,2
Mantle cell lymphoma,MITOXANTRONE,2,Completed,TOP2A,2
leiomyosarcoma,DOXORUBICIN,2,Completed,TOP2A,2
neoplasm,DOXORUBICIN,1,"Active, not recruiting",TOP2A,2
leukemia,ETOPOSIDE,1,"Active, not recruiting",TOP2A,2
soft tissue sarcoma,DOXORUBICIN,2,Not yet recruiting,TOP2A,2
Malignant epithelial tumor of ovary,DOXORUBICIN,1,Completed,TOP2A,2
leukemia,ETOPOSIDE,2,"Active, not recruiting",TOP2A,2
lymphoma,ETOPOSIDE,4,Recruiting,TOP2A,2
soft tissue sarcoma,DOXORUBICIN,2,Terminated,TOP2A,2
leukemia,ETOPOSIDE,3,"Active, not recruiting",TOP2A,2
soft tissue sarcoma,DOXORUBICIN,3,Completed,TOP2A,2
myelodysplastic syndrome,MITOXANTRONE,1,"Active, not recruiting",TOP2A,2
myelodysplastic syndrome,IDARUBICIN,3,Unknown status,TOP2A,2
leukemia,IDARUBICIN,2,Recruiting,TOP2A,2
leukemia,IDARUBICIN,2,Terminated,TOP2A,2
myelodysplastic syndrome,IDARUBICIN,2,Recruiting,TOP2A,2
Hodgkins lymphoma,ETOPOSIDE,3,Recruiting,TOP2A,2
myelodysplastic syndrome,IDARUBICIN,1,Recruiting,TOP2A,2
Hodgkins lymphoma,ETOPOSIDE,3,Completed,TOP2A,2
myelodysplastic syndrome,IDARUBICIN,1,"Active, not recruiting",TOP2A,2
leukemia,DOXORUBICIN,2,Terminated,TOP2A,2
acute myeloid leukemia,ETOPOSIDE,2,Not yet recruiting,TOP2A,2
breast carcinoma,DOXORUBICIN,2,Suspended,TOP2A,2
acute lymphoblastic leukemia,MITOXANTRONE,4,Completed,TOP2A,2
renal cell carcinoma,DOXORUBICIN,2,Completed,TOP2A,2
renal carcinoma,ETOPOSIDE,3,Completed,TOP2A,2
acute myeloid leukemia,MITOXANTRONE,2,Terminated,TOP2A,2
acute lymphoblastic leukemia,ETOPOSIDE,2,Terminated,TOP2A,2
peritoneal neoplasm,DOXORUBICIN,3,Completed,TOP2A,2
acute myeloid leukemia,MITOXANTRONE,2,Not yet recruiting,TOP2A,2
renal carcinoma,DOXORUBICIN,3,Completed,TOP2A,2
peritoneal neoplasm,DOXORUBICIN,2,Unknown status,TOP2A,2
renal carcinoma,DOXORUBICIN,2,Unknown status,TOP2A,2
breast carcinoma,ETOPOSIDE,2,Unknown status,TOP2A,2
acute myeloid leukemia,DAUNORUBICIN,1,Terminated,TOP2A,2
medulloblastoma,ETOPOSIDE,2,Recruiting,TOP2A,2
breast carcinoma,MITOXANTRONE,2,Completed,TOP2A,2
acute myeloid leukemia,DAUNORUBICIN,1,Withdrawn,TOP2A,2
ovarian carcinoma,DOXORUBICIN,2,Recruiting,TOP2A,2
acute myeloid leukemia,IDARUBICIN,4,Completed,TOP2A,2
acute myeloid leukemia,DAUNORUBICIN,2,Terminated,TOP2A,2
breast carcinoma,MITOXANTRONE,2,Unknown status,TOP2A,2
prostate carcinoma,DOXORUBICIN,3,Completed,TOP2A,2
acute myeloid leukemia,IDARUBICIN,3,"Active, not recruiting",TOP2A,2
prostate carcinoma,DOXORUBICIN,3,Terminated,TOP2A,2
breast carcinoma,DOXORUBICIN,4,Unknown status,TOP2A,2
prostate adenocarcinoma,MITOXANTRONE,3,Completed,TOP2A,2
breast carcinoma,DOXORUBICIN,4,Recruiting,TOP2A,2
acute lymphoblastic leukemia,MITOXANTRONE,2,Terminated,TOP2A,2
ovarian carcinoma,DOXORUBICIN,2,Not yet recruiting,TOP2A,2
breast carcinoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,2
acute promyelocytic leukemia,DAUNORUBICIN,4,Unknown status,TOP2A,2
primitive neuroectodermal tumor,ETOPOSIDE,3,Completed,TOP2A,2
acute promyelocytic leukemia,IDARUBICIN,3,Recruiting,TOP2A,2
acute lymphoblastic leukemia,MITOXANTRONE,1,Recruiting,TOP2A,2
ovarian carcinoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,2
acute lymphoblastic leukemia,MITOXANTRONE,1,Completed,TOP2A,2
acute lymphoblastic leukemia,IDARUBICIN,4,Unknown status,TOP2A,2
acute promyelocytic leukemia,IDARUBICIN,4,Unknown status,TOP2A,2
acute lymphoblastic leukemia,ETOPOSIDE,3,"Active, not recruiting",TOP2A,2
acute lymphoblastic leukemia,IDARUBICIN,4,Recruiting,TOP2A,2
acute lymphoblastic leukemia,IDARUBICIN,4,Completed,TOP2A,2
acute lymphoblastic leukemia,IDARUBICIN,2,Recruiting,TOP2A,2
acute promyelocytic leukemia,MITOXANTRONE,3,Recruiting,TOP2A,2
acute lymphoblastic leukemia,ETOPOSIDE,4,Unknown status,TOP2A,2
sarcoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,2
ovarian carcinoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,2
prostate adenocarcinoma,MITOXANTRONE,2,Terminated,TOP2A,2
acute lymphoblastic leukemia,ETOPOSIDE,3,Completed,TOP2A,2
ovarian carcinoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,2
acute myeloid leukemia,IDARUBICIN,4,Unknown status,TOP2A,2
ovarian neoplasm,DOXORUBICIN,3,Terminated,TOP2A,2
cancer,ETOPOSIDE,1,Completed,TOP2A,2
bladder carcinoma,DOXORUBICIN,2,Recruiting,TOP2A,2
breast neoplasm,DOXORUBICIN,2,Terminated,TOP2A,2
cancer,DOXORUBICIN,1,"Active, not recruiting",TOP2A,2
acute lymphoblastic leukemia,DOXORUBICIN,4,Unknown status,TOP2A,2
breast neoplasm,DOXORUBICIN,4,Terminated,TOP2A,2
ovarian neoplasm,DOXORUBICIN,3,Completed,TOP2A,2
acute myeloid leukemia,ETOPOSIDE,1,Recruiting,TOP2A,2
ovarian carcinoma,MITOXANTRONE,1,Completed,TOP2A,2
pancreatic carcinoma,DOXORUBICIN,2,Terminated,TOP2A,2
prostate carcinoma,MITOXANTRONE,3,Completed,TOP2A,2
prostate carcinoma,MITOXANTRONE,1,Unknown status,TOP2A,2
osteosarcoma,ETOPOSIDE,2,Completed,TOP2A,2
ovarian carcinoma,ETOPOSIDE,1,Terminated,TOP2A,2
acute myeloid leukemia,ETOPOSIDE,2,Unknown status,TOP2A,2
acute myeloid leukemia,ETOPOSIDE,2,Terminated,TOP2A,2
peritoneal neoplasm,DOXORUBICIN,1,Recruiting,TOP2A,2
acute lymphoblastic leukemia,DOXORUBICIN,3,"Active, not recruiting",TOP2A,2
ovarian neoplasm,DOXORUBICIN,4,Completed,TOP2A,1
testicular neoplasm,ETOPOSIDE,3,Recruiting,TOP2A,1
pain,MITOXANTRONE,3,Completed,TOP2A,1
myelodysplastic syndrome,DOXORUBICIN,2,Recruiting,TOP2A,1
pancreatic carcinoma,ALDOXORUBICIN,1,"Active, not recruiting",TOP2A,1
soft tissue sarcoma,DOXORUBICIN,2,Unknown status,TOP2A,1
plasma cell leukemia,DOXORUBICIN,2,Unknown status,TOP2A,1
myelodysplastic syndrome,DOXORUBICIN,1,Recruiting,TOP2A,1
squamous cell lung carcinoma,ETOPOSIDE,3,Unknown status,TOP2A,1
myelodysplastic syndrome,MITOXANTRONE,3,Completed,TOP2A,1
thymus neoplasm,ETOPOSIDE,3,Recruiting,TOP2A,1
myelodysplastic syndrome,VOSAROXIN,1,"Active, not recruiting",TOP2A,1
testicular neoplasm,ETOPOSIDE,3,Completed,TOP2A,1
myelodysplastic syndrome,DOXORUBICIN,1,Completed,TOP2A,1
ovarian neoplasm,DOXORUBICIN,3,Recruiting,TOP2A,1
plasma cell leukemia,ETOPOSIDE,1,Recruiting,TOP2A,1
ovarian neoplasm,DOXORUBICIN,2,Terminated,TOP2A,1
precursor T-cell lymphoblastic leukemia-lymphoma,MITOXANTRONE,1,Terminated,TOP2A,1
myelodysplastic syndrome,DAUNORUBICIN,2,Terminated,TOP2A,1
primitive neuroectodermal tumor,ETOPOSIDE,2,Completed,TOP2A,1
soft tissue sarcoma,DOXORUBICIN,2,Completed,TOP2A,1
myelodysplastic syndrome,DAUNORUBICIN,1,"Active, not recruiting",TOP2A,1
pancreatic carcinoma,ALDOXORUBICIN,1,Recruiting,TOP2A,1
myelodysplastic syndrome,MITOXANTRONE,2,Recruiting,TOP2A,1
soft tissue sarcoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
soft tissue sarcoma,ETOPOSIDE,2,Recruiting,TOP2A,1
squamous cell lung carcinoma,ETOPOSIDE,1,Terminated,TOP2A,1
squamous cell carcinoma,ALDOXORUBICIN,1,Recruiting,TOP2A,1
myelodysplastic syndrome,IDARUBICIN,3,Completed,TOP2A,1
rhabdomyosarcoma,DOXORUBICIN,2,Completed,TOP2A,1
soft tissue sarcoma,IDARUBICIN,3,Recruiting,TOP2A,1
peritoneal neoplasm,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
peritoneal neoplasm,DOXORUBICIN,2,Completed,TOP2A,1
testicular carcinoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
rhabdomyosarcoma,DOXORUBICIN,2,Recruiting,TOP2A,1
pancreatic ductal adenocarcinoma,ALDOXORUBICIN,2,Completed,TOP2A,1
soft tissue sarcoma,ETOPOSIDE,3,Recruiting,TOP2A,1
testicular neoplasm,ETOPOSIDE,2,Completed,TOP2A,1
myelodysplastic syndrome,IDARUBICIN,1,Completed,TOP2A,1
peritoneal neoplasm,DOXORUBICIN,2,Terminated,TOP2A,1
pancreatic carcinoma,ETOPOSIDE,2,Completed,TOP2A,1
myelodysplastic syndrome,MITOXANTRONE,2,Terminated,TOP2A,1
myelodysplastic syndrome,ETOPOSIDE,3,Unknown status,TOP2A,1
myelodysplastic syndrome,IDARUBICIN,4,Completed,TOP2A,1
soft tissue sarcoma,DOXORUBICIN,4,Recruiting,TOP2A,1
myelodysplastic syndrome,MITOXANTRONE,1,Completed,TOP2A,1
myelodysplastic syndrome,ETOPOSIDE,2,Recruiting,TOP2A,1
peritoneal neoplasm,ETOPOSIDE,1,Completed,TOP2A,1
peritoneal neoplasm,ETOPOSIDE,1,Terminated,TOP2A,1
myelodysplastic syndrome,MITOXANTRONE,2,Completed,TOP2A,1
myelodysplastic syndrome,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
myelodysplastic syndrome,ETOPOSIDE,1,Recruiting,TOP2A,1
peritoneal neoplasm,ETOPOSIDE PHOSPHATE,1,Unknown status,TOP2A,1
plasma cell leukemia,DOXORUBICIN,1,Withdrawn,TOP2A,1
squamous cell lung carcinoma,ETOPOSIDE,3,Completed,TOP2A,1
pancreatic carcinoma,ALDOXORUBICIN,2,Not yet recruiting,TOP2A,1
multiple sclerosis,MITOXANTRONE,3,"Active, not recruiting",TOP2A,1
oligoastrocytoma,ETOPOSIDE,1,Recruiting,TOP2A,1
multiple sclerosis,MITOXANTRONE,2,Unknown status,TOP2A,1
multiple myeloma,DOXORUBICIN,1,Recruiting,TOP2A,1
prostate carcinoma,ETOPOSIDE,3,Completed,TOP2A,1
multiple myeloma,DOXORUBICIN,1,Withdrawn,TOP2A,1
prostate carcinoma,ETOPOSIDE,2,Terminated,TOP2A,1
refractory anemia,DAUNORUBICIN,2,Unknown status,TOP2A,1
urothelial carcinoma,VALRUBICIN,1,Completed,TOP2A,1
urethral neoplasm,DOXORUBICIN,3,Completed,TOP2A,1
refractory anemia,ETOPOSIDE,2,Unknown status,TOP2A,1
refractory anemia,IDARUBICIN,2,Unknown status,TOP2A,1
urethral neoplasm,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
ureteral neoplasm,DOXORUBICIN,2,Completed,TOP2A,1
unspecified peripheral T-cell lymphoma,ETOPOSIDE,4,Recruiting,TOP2A,1
unspecified peripheral T-cell lymphoma,ETOPOSIDE,2,Recruiting,TOP2A,1
unspecified peripheral T-cell lymphoma,ETOPOSIDE,2,Completed,TOP2A,1
relapsing-remitting multiple sclerosis,ETOPOSIDE,2,Completed,TOP2A,1
unspecified peripheral T-cell lymphoma,ETOPOSIDE,1,Recruiting,TOP2A,1
uterine leiomyosarcoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
prostate carcinoma,MITOXANTRONE,3,"Active, not recruiting",TOP2A,1
multiple sclerosis,MITOXANTRONE,2,"Active, not recruiting",TOP2A,1
uterine neoplasm,DOXORUBICIN,1,Recruiting,TOP2A,1
medulloblastoma,ETOPOSIDE PHOSPHATE,2,Recruiting,TOP2A,1
mesothelioma,DOXORUBICIN,2,Completed,TOP2A,1
prostate carcinoma,MITOXANTRONE,2,"Active, not recruiting",TOP2A,1
prostate carcinoma,MITOXANTRONE,2,Terminated,TOP2A,1
mesothelioma,DOXORUBICIN,3,Unknown status,TOP2A,1
metastasis,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
metastatic colorectal cancer,ALDOXORUBICIN,1,Recruiting,TOP2A,1
uterine neoplasm,DOXORUBICIN,3,Unknown status,TOP2A,1
metastatic colorectal cancer,DOXORUBICIN,2,Terminated,TOP2A,1
metastatic prostate cancer,MITOXANTRONE,2,Terminated,TOP2A,1
prostate carcinoma,MITOXANTRONE,1,Recruiting,TOP2A,1
multiple myeloma,AMRUBICIN,1,Completed,TOP2A,1
prostate carcinoma,MITOXANTRONE,2,Unknown status,TOP2A,1
multiple myeloma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
prostate carcinoma,MITOXANTRONE,2,Withdrawn,TOP2A,1
unspecified peripheral T-cell lymphoma,DOXORUBICIN,4,Recruiting,TOP2A,1
relapsing-remitting multiple sclerosis,MITOXANTRONE,2,Terminated,TOP2A,1
unspecified peripheral T-cell lymphoma,DOXORUBICIN,4,Completed,TOP2A,1
renal carcinoma,BECATECARIN,2,Completed,TOP2A,1
prostate adenocarcinoma,MITOXANTRONE,2,Completed,TOP2A,1
rhabdomyosarcoma,DOXORUBICIN,4,Unknown status,TOP2A,1
prostate adenocarcinoma,MITOXANTRONE,1,Completed,TOP2A,1
renal cell carcinoma,DOXORUBICIN,2,Recruiting,TOP2A,1
multiple myeloma,ETOPOSIDE,2,Unknown status,TOP2A,1
multiple myeloma,ETOPOSIDE,2,Withdrawn,TOP2A,1
multiple myeloma,ETOPOSIDE,3,"Active, not recruiting",TOP2A,1
prostate adenocarcinoma,DOXORUBICIN,2,Terminated,TOP2A,1
thyroid carcinoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
prostate adenocarcinoma,DOXORUBICIN,2,Completed,TOP2A,1
multiple myeloma,ETOPOSIDE,3,Recruiting,TOP2A,1
multiple myeloma,ETOPOSIDE PHOSPHATE,1,Completed,TOP2A,1
multiple myeloma,IDARUBICIN,2,Unknown status,TOP2A,1
multiple myeloma,IDARUBICIN,3,Completed,TOP2A,1
multiple myeloma,MITOXANTRONE,2,Terminated,TOP2A,1
multiple myeloma,ETOPOSIDE,2,Not yet recruiting,TOP2A,1
multiple myeloma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
renal carcinoma,ETOPOSIDE,3,Unknown status,TOP2A,1
triple-negative breast cancer,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
unspecified peripheral T-cell lymphoma,DOXORUBICIN,3,Not yet recruiting,TOP2A,1
unspecified peripheral T-cell lymphoma,DOXORUBICIN,3,Completed,TOP2A,1
unspecified peripheral T-cell lymphoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
unspecified peripheral T-cell lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
unspecified peripheral T-cell lymphoma,DOXORUBICIN,1,Recruiting,TOP2A,1
unspecified peripheral T-cell lymphoma,DOXORUBICIN,1,Completed,TOP2A,1
triple-negative breast cancer,DOXORUBICIN,2,Recruiting,TOP2A,1
multiple myeloma,DOXORUBICIN,4,"Active, not recruiting",TOP2A,1
transitional cell carcinoma of kidney,DOXORUBICIN,3,Completed,TOP2A,1
multiple myeloma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
renal carcinoma,DOXORUBICIN,3,Unknown status,TOP2A,1
prostate carcinoma,DOXORUBICIN,1,Terminated,TOP2A,1
multiple myeloma,DOXORUBICIN,3,Recruiting,TOP2A,1
renal carcinoma,ETOPOSIDE,2,Unknown status,TOP2A,1
soft tissue sarcoma,DOXORUBICIN,1,Recruiting,TOP2A,1
small intestine carcinoma,BECATECARIN,1,Completed,TOP2A,1
ovarian neoplasm,DOXORUBICIN,1,Recruiting,TOP2A,1
sarcoma,ETOPOSIDE,3,Withdrawn,TOP2A,1
sarcoma,ETOPOSIDE,3,Terminated,TOP2A,1
neuroblastoma,ETOPOSIDE,2,Unknown status,TOP2A,1
neuroblastoma,ETOPOSIDE,3,Recruiting,TOP2A,1
sarcoma,ETOPOSIDE,3,Recruiting,TOP2A,1
neuroblastoma,ETOPOSIDE PHOSPHATE,2,Completed,TOP2A,1
neuromyelitis optica,MITOXANTRONE,4,Unknown status,TOP2A,1
nodular sclerosis Hodgkin lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
nodular sclerosis Hodgkin lymphoma,DOXORUBICIN,2,Completed,TOP2A,1
nodular sclerosis Hodgkin lymphoma,DOXORUBICIN,3,Unknown status,TOP2A,1
nodular sclerosis Hodgkin lymphoma,ETOPOSIDE PHOSPHATE,3,Unknown status,TOP2A,1
non-Hodgkins lymphoma,DAUNORUBICIN,3,Completed,TOP2A,1
ovarian carcinoma,DOXORUBICIN,1,Not yet recruiting,TOP2A,1
sarcoma,ETOPOSIDE,3,"Active, not recruiting",TOP2A,1
sarcoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
non-Hodgkins lymphoma,DOXORUBICIN,1,Recruiting,TOP2A,1
non-Hodgkins lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
ovarian carcinoma,BECATECARIN,2,Terminated,TOP2A,1
sarcoma,DOXORUBICIN,2,Withdrawn,TOP2A,1
neuroblastoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
ovarian neoplasm,DOXORUBICIN,1,Completed,TOP2A,1
secondary progressive multiple sclerosis,MITOXANTRONE,3,Terminated,TOP2A,1
sarcoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
sarcoma,DOXORUBICIN,1,Not yet recruiting,TOP2A,1
sarcoma,DOXORUBICIN,1,Suspended,TOP2A,1
neuroblastoma,DOXORUBICIN,2,Terminated,TOP2A,1
small cell lung carcinoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
small cell lung carcinoma,DOXORUBICIN,2,Completed,TOP2A,1
small cell lung carcinoma,DOXORUBICIN,1,Terminated,TOP2A,1
small cell lung carcinoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
neuroblastoma,DOXORUBICIN,3,Recruiting,TOP2A,1
small cell lung carcinoma,BECATECARIN,2,Terminated,TOP2A,1
small cell lung carcinoma,AMRUBICIN,3,Terminated,TOP2A,1
small cell lung carcinoma,AMRUBICIN,3,Completed,TOP2A,1
ovarian carcinoma,DOXORUBICIN,1,Withdrawn,TOP2A,1
small cell lung carcinoma,AMRUBICIN,2,Terminated,TOP2A,1
small cell lung carcinoma,ALDOXORUBICIN,2,Withdrawn,TOP2A,1
small cell lung carcinoma,ALDOXORUBICIN,2,Unknown status,TOP2A,1
neuroblastoma,ETOPOSIDE,1,Unknown status,TOP2A,1
non-Hodgkins lymphoma,DOXORUBICIN,2,Unknown status,TOP2A,1
sarcoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
osteosarcoma,ETOPOSIDE,3,Completed,TOP2A,1
non-Hodgkins lymphoma,DOXORUBICIN,3,Recruiting,TOP2A,1
non-small cell lung carcinoma,ALDOXORUBICIN,2,Not yet recruiting,TOP2A,1
non-small cell lung carcinoma,DOXORUBICIN,1,Unknown status,TOP2A,1
non-small cell lung carcinoma,DOXORUBICIN,2,Not yet recruiting,TOP2A,1
sarcoma,DOXORUBICIN,3,Terminated,TOP2A,1
osteosarcoma,DOXORUBICIN,1,Terminated,TOP2A,1
non-small cell lung carcinoma,ETOPOSIDE,1,Recruiting,TOP2A,1
osteosarcoma,DOXORUBICIN,1,Completed,TOP2A,1
non-small cell lung carcinoma,ETOPOSIDE,1,Unknown status,TOP2A,1
sarcoma,DOXORUBICIN,3,Withdrawn,TOP2A,1
optic nerve glioblastoma,ETOPOSIDE,1,Recruiting,TOP2A,1
optic nerve glioblastoma,DOXORUBICIN,1,Recruiting,TOP2A,1
oligodendroglioma,ETOPOSIDE,1,Recruiting,TOP2A,1
non-small cell lung carcinoma,ETOPOSIDE,2,Unknown status,TOP2A,1
non-small cell lung carcinoma,ETOPOSIDE,2,Withdrawn,TOP2A,1
oligodendroglioma,DOXORUBICIN,1,Recruiting,TOP2A,1
non-small cell lung carcinoma,ETOPOSIDE,3,Terminated,TOP2A,1
non-small cell lung carcinoma,VOSAROXIN,2,Completed,TOP2A,1
non-Hodgkins lymphoma,MITOXANTRONE,3,Completed,TOP2A,1
sarcoma,ETOPOSIDE,1,"Active, not recruiting",TOP2A,1
non-Hodgkins lymphoma,MITOXANTRONE,1,Unknown status,TOP2A,1
non-Hodgkins lymphoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
non-Hodgkins lymphoma,DOXORUBICIN,3,Terminated,TOP2A,1
non-Hodgkins lymphoma,DOXORUBICIN,4,Completed,TOP2A,1
non-Hodgkins lymphoma,DOXORUBICIN,4,Unknown status,TOP2A,1
osteosarcoma,ETOPOSIDE,3,"Active, not recruiting",TOP2A,1
osteosarcoma,ETOPOSIDE,1,Terminated,TOP2A,1
non-Hodgkins lymphoma,ETOPOSIDE,1,Terminated,TOP2A,1
non-Hodgkins lymphoma,ETOPOSIDE,1,Withdrawn,TOP2A,1
osteosarcoma,DOXORUBICIN,3,Completed,TOP2A,1
non-Hodgkins lymphoma,IDARUBICIN,3,Recruiting,TOP2A,1
osteosarcoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
non-Hodgkins lymphoma,ETOPOSIDE,3,Completed,TOP2A,1
osteosarcoma,DOXORUBICIN,2,Unknown status,TOP2A,1
non-Hodgkins lymphoma,ETOPOSIDE,4,Unknown status,TOP2A,1
non-Hodgkins lymphoma,ETOPOSIDE PHOSPHATE,1,Completed,TOP2A,1
non-Hodgkins lymphoma,ETOPOSIDE PHOSPHATE,2,Completed,TOP2A,1
sarcoma,DOXORUBICIN,3,Not yet recruiting,TOP2A,1
sarcoma,DAUNORUBICIN,3,Completed,TOP2A,1
small cell lung carcinoma,ETOPOSIDE,2,Suspended,TOP2A,1
neuroblastoma,BECATECARIN,2,Completed,TOP2A,1
small cell lung carcinoma,ETOPOSIDE,3,Terminated,TOP2A,1
neoplasm,AMSACRINE,4,n/a,TOP2A,1
neoplasm,BECATECARIN,1,Terminated,TOP2A,1
neoplasm,DAUNORUBICIN,4,n/a,TOP2A,1
rhabdomyosarcoma,ETOPOSIDE,3,Terminated,TOP2A,1
rhabdomyosarcoma,ETOPOSIDE PHOSPHATE,2,Recruiting,TOP2A,1
ovarian carcinoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
neoplasm,DOXORUBICIN,1,Unknown status,TOP2A,1
neoplasm,DOXORUBICIN,3,Completed,TOP2A,1
neoplasm,DOXORUBICIN,3,Unknown status,TOP2A,1
neoplasm,DOXORUBICIN,4,n/a,TOP2A,1
neoplasm,ETOPOSIDE,0,Terminated,TOP2A,1
small cell lung carcinoma,VOSAROXIN,2,Completed,TOP2A,1
neoplasm,ETOPOSIDE,1,Not yet recruiting,TOP2A,1
ovarian carcinoma,ETOPOSIDE,1,Completed,TOP2A,1
small cell lung carcinoma,ETOPOSIDE,4,Unknown status,TOP2A,1
small cell lung carcinoma,ETOPOSIDE,3,Withdrawn,TOP2A,1
neoplasm,ETOPOSIDE,1,Recruiting,TOP2A,1
neoplasm,AMRUBICIN,4,n/a,TOP2A,1
neoplasm,AMRUBICIN,1,Completed,TOP2A,1
rhabdomyosarcoma,ETOPOSIDE,2,Recruiting,TOP2A,1
ovarian carcinoma,ETOPOSIDE,2,Not yet recruiting,TOP2A,1
ovarian carcinoma,MITOXANTRONE,3,Terminated,TOP2A,1
ovarian carcinoma,MITOXANTRONE,2,Completed,TOP2A,1
ovarian carcinoma,ETOPOSIDE PHOSPHATE,1,Unknown status,TOP2A,1
myeloid sarcoma,DAUNORUBICIN,3,"Active, not recruiting",TOP2A,1
soft tissue sarcoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
myeloid sarcoma,ETOPOSIDE,3,"Active, not recruiting",TOP2A,1
ovarian carcinoma,ETOPOSIDE,2,Recruiting,TOP2A,1
soft tissue sarcoma,AMRUBICIN,2,Completed,TOP2A,1
nasopharyngeal neoplasm,DOXORUBICIN,2,Terminated,TOP2A,1
myeloid sarcoma,MITOXANTRONE,3,"Active, not recruiting",TOP2A,1
rhabdomyosarcoma,ETOPOSIDE,2,Completed,TOP2A,1
small intestine carcinoma,ETOPOSIDE,1,Completed,TOP2A,1
myeloproliferative disorder,DAUNORUBICIN,3,Completed,TOP2A,1
myeloproliferative disorder,DOXORUBICIN,1,Completed,TOP2A,1
myeloproliferative disorder,ETOPOSIDE,1,Completed,TOP2A,1
oligoastrocytoma,DOXORUBICIN,1,Recruiting,TOP2A,1
salivary gland neoplasm,DOXORUBICIN,2,Recruiting,TOP2A,1
neoplasm,ETOPOSIDE,1,Terminated,TOP2A,1
neoplasm of mature T-cells or NK-cells,ETOPOSIDE,2,Recruiting,TOP2A,1
small cell lung carcinoma,ETOPOSIDE,3,Recruiting,TOP2A,1
ovarian carcinoma,DOXORUBICIN,2,Withdrawn,TOP2A,1
neoplasm of mature B-cells,DOXORUBICIN,2,Unknown status,TOP2A,1
sarcoma,ALDOXORUBICIN,2,Unknown status,TOP2A,1
sarcoma,ALDOXORUBICIN,3,Completed,TOP2A,1
neoplasm of mature B-cells,DOXORUBICIN,3,Completed,TOP2A,1
neoplasm of mature B-cells,DOXORUBICIN,3,Terminated,TOP2A,1
neoplasm of mature B-cells,DOXORUBICIN,3,Unknown status,TOP2A,1
neoplasm of mature B-cells,ETOPOSIDE,1,"Active, not recruiting",TOP2A,1
neoplasm of mature B-cells,ETOPOSIDE,1,Terminated,TOP2A,1
neoplasm of mature B-cells,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
neoplasm of mature B-cells,ETOPOSIDE,2,Completed,TOP2A,1
small cell lung carcinoma,ETOPOSIDE,2,Terminated,TOP2A,1
neoplasm of mature B-cells,ETOPOSIDE,2,Recruiting,TOP2A,1
neoplasm of mature B-cells,ETOPOSIDE,3,Recruiting,TOP2A,1
sarcoma,DAUNORUBICIN,1,Terminated,TOP2A,1
neoplasm of mature B-cells,MITOXANTRONE,3,Terminated,TOP2A,1
neoplasm of mature T-cells or NK-cells,ETOPOSIDE,2,Completed,TOP2A,1
small cell lung carcinoma,ETOPOSIDE,2,Withdrawn,TOP2A,1
neoplasm of mature B-cells,DOXORUBICIN,2,Not yet recruiting,TOP2A,1
neoplasm of mature B-cells,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
sarcoma,ALDOXORUBICIN,1,Unknown status,TOP2A,1
neoplasm,ETOPOSIDE,1,Unknown status,TOP2A,1
neoplasm,ETOPOSIDE,1,Withdrawn,TOP2A,1
neoplasm,ETOPOSIDE,2,Recruiting,TOP2A,1
neoplasm,ETOPOSIDE,2,Terminated,TOP2A,1
ovarian carcinoma,DOXORUBICIN,3,Terminated,TOP2A,1
neoplasm,ETOPOSIDE,3,"Active, not recruiting",TOP2A,1
neoplasm,ETOPOSIDE,3,Completed,TOP2A,1
neoplasm,ETOPOSIDE PHOSPHATE,4,n/a,TOP2A,1
neoplasm of mature B-cells,DOXORUBICIN,1,Completed,TOP2A,1
neoplasm,IDARUBICIN,4,n/a,TOP2A,1
ovarian carcinoma,DOXORUBICIN,3,Suspended,TOP2A,1
neoplasm,MITOXANTRONE,4,n/a,TOP2A,1
neoplasm,TENIPOSIDE,4,n/a,TOP2A,1
neoplasm,VALRUBICIN,4,n/a,TOP2A,1
ovarian carcinoma,DOXORUBICIN,3,Recruiting,TOP2A,1
neoplasm,VOSAROXIN,4,n/a,TOP2A,1
medulloblastoma,ETOPOSIDE,2,Unknown status,TOP2A,1
B-cell acute lymphoblastic leukemia,DOXORUBICIN,1,Recruiting,TOP2A,1
medulloblastoma,ETOPOSIDE,2,Completed,TOP2A,1
acute myeloid leukemia,IDARUBICIN,3,Terminated,TOP2A,1
acute myeloid leukemia,DOXORUBICIN,2,Recruiting,TOP2A,1
acute myeloid leukemia,DOXORUBICIN,2,Terminated,TOP2A,1
acute myeloid leukemia,ETOPOSIDE,0,Recruiting,TOP2A,1
acute myeloid leukemia,ETOPOSIDE,2,Withdrawn,TOP2A,1
acute myeloid leukemia,ETOPOSIDE,3,Recruiting,TOP2A,1
acute myeloid leukemia,ETOPOSIDE,4,Unknown status,TOP2A,1
acute myeloid leukemia,ETOPOSIDE PHOSPHATE,1,Completed,TOP2A,1
acute myeloid leukemia,IDARUBICIN,1,Terminated,TOP2A,1
acute myeloid leukemia,IDARUBICIN,1,Unknown status,TOP2A,1
acute myeloid leukemia,IDARUBICIN,2,Not yet recruiting,TOP2A,1
acute myeloid leukemia,IDARUBICIN,2,Withdrawn,TOP2A,1
acute myeloid leukemia,IDARUBICIN,3,Recruiting,TOP2A,1
acute myeloid leukemia,IDARUBICIN,3,Unknown status,TOP2A,1
acute lymphoblastic leukemia,IDARUBICIN,3,Completed,TOP2A,1
acute myeloid leukemia,MITOXANTRONE,2,Suspended,TOP2A,1
acute myeloid leukemia,MITOXANTRONE,2,Unknown status,TOP2A,1
acute myeloid leukemia,MITOXANTRONE,3,Unknown status,TOP2A,1
acute myeloid leukemia,MITOXANTRONE,4,"Active, not recruiting",TOP2A,1
acute myeloid leukemia,MITOXANTRONE,4,Completed,TOP2A,1
acute myeloid leukemia,VOSAROXIN,1,Completed,TOP2A,1
acute myeloid leukemia,VOSAROXIN,3,Completed,TOP2A,1
acute myelomonocytic leukemia,DAUNORUBICIN,3,Completed,TOP2A,1
acute myelomonocytic leukemia,ETOPOSIDE,3,Completed,TOP2A,1
acute promyelocytic leukemia,IDARUBICIN,2,Completed,TOP2A,1
acute promyelocytic leukemia,IDARUBICIN,3,Completed,TOP2A,1
acute promyelocytic leukemia,IDARUBICIN,4,Recruiting,TOP2A,1
acute myeloid leukemia,DOXORUBICIN,2,Not yet recruiting,TOP2A,1
acute myeloid leukemia,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
acute myeloid leukemia,DOXORUBICIN,1,Recruiting,TOP2A,1
acute myeloid leukemia,DAUNORUBICIN,4,n/a,TOP2A,1
acute lymphoblastic leukemia,MITOXANTRONE,1,Terminated,TOP2A,1
acute lymphoblastic leukemia,MITOXANTRONE,2,Completed,TOP2A,1
acute lymphoblastic leukemia,MITOXANTRONE,2,Not yet recruiting,TOP2A,1
acute lymphoblastic leukemia,MITOXANTRONE,3,Completed,TOP2A,1
acute lymphoblastic leukemia,MITOXANTRONE,3,Recruiting,TOP2A,1
acute lymphoblastic leukemia,MITOXANTRONE,4,Unknown status,TOP2A,1
acute lymphoblastic leukemia,TENIPOSIDE,3,Completed,TOP2A,1
acute lymphoblastic leukemia,TENIPOSIDE,4,Unknown status,TOP2A,1
acute lymphoblastic leukemia,VOSAROXIN,1,Completed,TOP2A,1
acute megakaryoblastic leukaemia,DAUNORUBICIN,3,Completed,TOP2A,1
acute megakaryoblastic leukaemia,ETOPOSIDE,3,Completed,TOP2A,1
acute monocytic leukemia,DAUNORUBICIN,3,Completed,TOP2A,1
acute monocytic leukemia,ETOPOSIDE,3,Completed,TOP2A,1
acute monocytic leukemia,IDARUBICIN,1,Withdrawn,TOP2A,1
acute myeloblastic leukemia without maturation,DAUNORUBICIN,3,Completed,TOP2A,1
acute myeloblastic leukemia without maturation,ETOPOSIDE,3,Completed,TOP2A,1
acute myeloid leukemia,AMSACRINE,3,Not yet recruiting,TOP2A,1
acute myeloid leukemia,AMSACRINE,4,Completed,TOP2A,1
acute myeloid leukemia,DAUNORUBICIN,0,Recruiting,TOP2A,1
acute myeloid leukemia,DAUNORUBICIN,1,Not yet recruiting,TOP2A,1
acute myeloid leukemia,DAUNORUBICIN,2,Unknown status,TOP2A,1
acute myeloid leukemia,DAUNORUBICIN,3,Enrolling by invitation,TOP2A,1
acute myeloid leukemia,DAUNORUBICIN,3,Terminated,TOP2A,1
acute myeloid leukemia,DAUNORUBICIN,4,"Active, not recruiting",TOP2A,1
acute myeloid leukemia,DAUNORUBICIN,4,Completed,TOP2A,1
acute promyelocytic leukemia,MITOXANTRONE,3,Completed,TOP2A,1
acute promyelocytic leukemia,MITOXANTRONE,4,Completed,TOP2A,1
acute promyelocytic leukemia,MITOXANTRONE,4,Recruiting,TOP2A,1
biliary tract neoplasm,BECATECARIN,3,Terminated,TOP2A,1
bladder carcinoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
bladder carcinoma,DOXORUBICIN,3,Recruiting,TOP2A,1
bladder carcinoma,DOXORUBICIN,3,Terminated,TOP2A,1
bladder carcinoma,VALRUBICIN,3,Unknown status,TOP2A,1
bladder transitional cell carcinoma,VALRUBICIN,3,Terminated,TOP2A,1
brain neoplasm,ETOPOSIDE,0,Recruiting,TOP2A,1
breast adenocarcinoma,DOXORUBICIN,1,Recruiting,TOP2A,1
breast adenocarcinoma,DOXORUBICIN,2,Recruiting,TOP2A,1
breast adenocarcinoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
breast adenocarcinoma,DOXORUBICIN,3,Recruiting,TOP2A,1
breast carcinoma,ALDOXORUBICIN,1,Recruiting,TOP2A,1
breast carcinoma,ALDOXORUBICIN,2,Not yet recruiting,TOP2A,1
breast carcinoma,AMRUBICIN,1,Completed,TOP2A,1
breast carcinoma,AMRUBICIN,2,Withdrawn,TOP2A,1
breast carcinoma,DAUNORUBICIN,1,Unknown status,TOP2A,1
breast carcinoma,DOXORUBICIN,1,Recruiting,TOP2A,1
breast carcinoma,DOXORUBICIN,3,Suspended,TOP2A,1
breast carcinoma,ETOPOSIDE,1,Completed,TOP2A,1
breast carcinoma,ETOPOSIDE,2,Recruiting,TOP2A,1
breast carcinoma,ETOPOSIDE,3,Completed,TOP2A,1
breast carcinoma,MITOXANTRONE,2,Recruiting,TOP2A,1
breast carcinoma,MM-302,1,Unknown status,TOP2A,1
breast carcinoma,MM-302,2,Terminated,TOP2A,1
breast neoplasm,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
breast neoplasm,DOXORUBICIN,1,Completed,TOP2A,1
bladder carcinoma,AMRUBICIN,2,Terminated,TOP2A,1
autoimmune thrombocytopenic purpura,DOXORUBICIN,2,Unknown status,TOP2A,1
acute promyelocytic leukemia,MITOXANTRONE,4,Unknown status,TOP2A,1
autoimmune disease,ETOPOSIDE,2,Recruiting,TOP2A,1
adenoid cystic carcinoma,DOXORUBICIN,2,Completed,TOP2A,1
adrenal cortex carcinoma,DOXORUBICIN,1,Completed,TOP2A,1
adrenal cortex carcinoma,DOXORUBICIN,3,Completed,TOP2A,1
adrenal cortex carcinoma,ETOPOSIDE,3,Completed,TOP2A,1
adrenal cortex carcinoma,ETOPOSIDE,3,Recruiting,TOP2A,1
adult T acute lymphoblastic leukemia,DAUNORUBICIN,3,Suspended,TOP2A,1
adult T acute lymphoblastic leukemia,DOXORUBICIN,3,Suspended,TOP2A,1
adult T acute lymphoblastic leukemia,ETOPOSIDE,3,Suspended,TOP2A,1
adult acute myeloid leukemia,DAUNORUBICIN,2,Recruiting,TOP2A,1
adult acute myeloid leukemia,IDARUBICIN,2,Recruiting,TOP2A,1
alveolar rhabdomyosarcoma,DOXORUBICIN,2,Completed,TOP2A,1
alveolar rhabdomyosarcoma,ETOPOSIDE,2,Completed,TOP2A,1
anaplastic astrocytoma,DOXORUBICIN,1,Recruiting,TOP2A,1
anaplastic astrocytoma,ETOPOSIDE,1,Recruiting,TOP2A,1
anaplastic large cell lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
anaplastic large cell lymphoma,DOXORUBICIN,2,Completed,TOP2A,1
anaplastic large cell lymphoma,DOXORUBICIN,2,Suspended,TOP2A,1
anaplastic large cell lymphoma,DOXORUBICIN,2,Terminated,TOP2A,1
anaplastic large cell lymphoma,ETOPOSIDE,1,Terminated,TOP2A,1
anaplastic large cell lymphoma,ETOPOSIDE,2,Completed,TOP2A,1
anaplastic large cell lymphoma,ETOPOSIDE,2,Suspended,TOP2A,1
angioimmunoblastic T-cell lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
angioimmunoblastic T-cell lymphoma,DOXORUBICIN,2,Completed,TOP2A,1
angioimmunoblastic T-cell lymphoma,DOXORUBICIN,2,Recruiting,TOP2A,1
angioimmunoblastic T-cell lymphoma,DOXORUBICIN,3,Unknown status,TOP2A,1
acute lymphoblastic leukemia,IDARUBICIN,3,Terminated,TOP2A,1
acute lymphoblastic leukemia,IDARUBICIN,2,Not yet recruiting,TOP2A,1
malignant pleural mesothelioma,DOXORUBICIN,2,Unknown status,TOP2A,1
Kaposi's sarcoma,DOXORUBICIN,2,Completed,TOP2A,1
Hodgkins lymphoma,DOXORUBICIN,3,Withdrawn,TOP2A,1
Hodgkins lymphoma,ETOPOSIDE,1,Withdrawn,TOP2A,1
Hodgkins lymphoma,ETOPOSIDE,2,Not yet recruiting,TOP2A,1
Hodgkins lymphoma,ETOPOSIDE,2,Terminated,TOP2A,1
Hodgkins lymphoma,ETOPOSIDE,2,Unknown status,TOP2A,1
Hodgkins lymphoma,ETOPOSIDE,3,"Active, not recruiting",TOP2A,1
Hodgkins lymphoma,ETOPOSIDE,4,Recruiting,TOP2A,1
Hodgkins lymphoma,ETOPOSIDE,4,Unknown status,TOP2A,1
Hodgkins lymphoma,ETOPOSIDE PHOSPHATE,1,Completed,TOP2A,1
Hodgkins lymphoma,ETOPOSIDE PHOSPHATE,2,Completed,TOP2A,1
Hodgkins lymphoma,ETOPOSIDE PHOSPHATE,3,Completed,TOP2A,1
Kaposi's sarcoma,DOXORUBICIN,1,Recruiting,TOP2A,1
Kaposi's sarcoma,DOXORUBICIN,3,Completed,TOP2A,1
acute lymphoblastic leukemia,IDARUBICIN,1,Recruiting,TOP2A,1
Kaposi's sarcoma,ETOPOSIDE,1,Completed,TOP2A,1
Kidney Medullary Carcinoma,DOXORUBICIN,2,Recruiting,TOP2A,1
"Lymphoma, AIDS-Related",DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
"Lymphoma, AIDS-Related",DOXORUBICIN,2,Terminated,TOP2A,1
"Lymphoma, AIDS-Related",ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
Malignant epithelial tumor of ovary,DOXORUBICIN,2,Recruiting,TOP2A,1
Mantle cell lymphoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
Mantle cell lymphoma,DOXORUBICIN,2,Not yet recruiting,TOP2A,1
Mantle cell lymphoma,DOXORUBICIN,2,Recruiting,TOP2A,1
Mantle cell lymphoma,DOXORUBICIN,4,Recruiting,TOP2A,1
Mantle cell lymphoma,ETOPOSIDE,2,Completed,TOP2A,1
Mantle cell lymphoma,ETOPOSIDE,3,Unknown status,TOP2A,1
Hodgkins lymphoma,DOXORUBICIN,3,Unknown status,TOP2A,1
Hodgkins lymphoma,DOXORUBICIN,2,Not yet recruiting,TOP2A,1
Hereditary breast and ovarian cancer syndrome,DOXORUBICIN,2,Recruiting,TOP2A,1
Hepatoblastoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
Burkitts lymphoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
Burkitts lymphoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
Burkitts lymphoma,ETOPOSIDE,2,Completed,TOP2A,1
Burkitts lymphoma,ETOPOSIDE,3,Completed,TOP2A,1
Burkitts lymphoma,ETOPOSIDE,3,Suspended,TOP2A,1
Chordoma,ALDOXORUBICIN,1,Not yet recruiting,TOP2A,1
Cutaneous T-cell lymphoma,DOXORUBICIN,1,Recruiting,TOP2A,1
Endometrial Clear Cell Adenocarcinoma,DOXORUBICIN,1,Completed,TOP2A,1
Endometrial Serous Adenocarcinoma,DOXORUBICIN,1,Completed,TOP2A,1
Ewing sarcoma,DOXORUBICIN,1,Completed,TOP2A,1
Ewing sarcoma,DOXORUBICIN,2,Recruiting,TOP2A,1
Ewing sarcoma,DOXORUBICIN,3,Recruiting,TOP2A,1
Ewing sarcoma,ETOPOSIDE,2,Recruiting,TOP2A,1
Ewing sarcoma,ETOPOSIDE,2,Terminated,TOP2A,1
Ewing sarcoma,ETOPOSIDE,3,Recruiting,TOP2A,1
Fallopian Tube Carcinoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
Fallopian Tube Carcinoma,DOXORUBICIN,2,Completed,TOP2A,1
Fallopian Tube Carcinoma,DOXORUBICIN,2,Terminated,TOP2A,1
Fallopian Tube Carcinoma,DOXORUBICIN,3,Completed,TOP2A,1
Fallopian Tube Carcinoma,ETOPOSIDE,1,Completed,TOP2A,1
Fallopian Tube Carcinoma,ETOPOSIDE,1,Terminated,TOP2A,1
Fallopian Tube Carcinoma,ETOPOSIDE PHOSPHATE,1,Unknown status,TOP2A,1
Gestational trophoblastic neoplasm,ETOPOSIDE,3,Recruiting,TOP2A,1
Granulocytic Sarcoma,MITOXANTRONE,2,Recruiting,TOP2A,1
HIV-1 infection,ETOPOSIDE,3,"Active, not recruiting",TOP2A,1
Mantle cell lymphoma,ETOPOSIDE,4,Recruiting,TOP2A,1
Merkel cell skin cancer,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
Nephroblastoma,ETOPOSIDE,3,Completed,TOP2A,1
acute basophilic leukemia,DAUNORUBICIN,3,Completed,TOP2A,1
acute erythroblastic leukemia,IDARUBICIN,1,Withdrawn,TOP2A,1
acute erythroleukemia,DAUNORUBICIN,3,Completed,TOP2A,1
acute erythroleukemia,ETOPOSIDE,3,Completed,TOP2A,1
acute graft vs. host disease,ETOPOSIDE,1,Completed,TOP2A,1
acute lymphoblastic leukemia,DAUNORUBICIN,2,"Active, not recruiting",TOP2A,1
acute lymphoblastic leukemia,DAUNORUBICIN,2,Not yet recruiting,TOP2A,1
acute lymphoblastic leukemia,DAUNORUBICIN,2,Recruiting,TOP2A,1
acute lymphoblastic leukemia,DAUNORUBICIN,3,Completed,TOP2A,1
acute lymphoblastic leukemia,DAUNORUBICIN,3,Terminated,TOP2A,1
acute lymphoblastic leukemia,DAUNORUBICIN,3,Unknown status,TOP2A,1
acute lymphoblastic leukemia,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
acute lymphoblastic leukemia,DOXORUBICIN,1,Not yet recruiting,TOP2A,1
acute lymphoblastic leukemia,DOXORUBICIN,2,Not yet recruiting,TOP2A,1
acute lymphoblastic leukemia,DOXORUBICIN,2,Terminated,TOP2A,1
acute lymphoblastic leukemia,DOXORUBICIN,3,Completed,TOP2A,1
acute lymphoblastic leukemia,DOXORUBICIN,3,Terminated,TOP2A,1
acute lymphoblastic leukemia,DOXORUBICIN,3,Unknown status,TOP2A,1
acute lymphoblastic leukemia,ETOPOSIDE,0,Completed,TOP2A,1
acute lymphoblastic leukemia,ETOPOSIDE,1,Recruiting,TOP2A,1
acute lymphoblastic leukemia,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
acute lymphoblastic leukemia,ETOPOSIDE,2,Not yet recruiting,TOP2A,1
acute lymphoblastic leukemia,ETOPOSIDE,2,Withdrawn,TOP2A,1
acute lymphoblastic leukemia,ETOPOSIDE,3,Terminated,TOP2A,1
acute lymphoblastic leukemia,ETOPOSIDE,4,Recruiting,TOP2A,1
acute lymphoblastic leukemia,ETOPOSIDE PHOSPHATE,2,"Active, not recruiting",TOP2A,1
acute basophilic leukemia,ETOPOSIDE,3,Completed,TOP2A,1
abnormality of blood and blood-forming tissues,ETOPOSIDE,2,Terminated,TOP2A,1
Primary hemophagocytic lymphohistiocytosis,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
Primary hemophagocytic lymphohistiocytosis,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
Primary hemophagocytic lymphohistiocytosis,ETOPOSIDE,2,Completed,TOP2A,1
Primary hemophagocytic lymphohistiocytosis,ETOPOSIDE,3,Completed,TOP2A,1
Primary hemophagocytic lymphohistiocytosis,ETOPOSIDE,3,Not yet recruiting,TOP2A,1
Primary systemic amyloidosis,DOXORUBICIN,1,Terminated,TOP2A,1
Retinoblastoma,DOXORUBICIN,2,Completed,TOP2A,1
Retinoblastoma,DOXORUBICIN,2,Recruiting,TOP2A,1
Retinoblastoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
Retinoblastoma,ETOPOSIDE,1,"Active, not recruiting",TOP2A,1
Retinoblastoma,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
Retinoblastoma,ETOPOSIDE,3,Completed,TOP2A,1
Retinoblastoma,ETOPOSIDE,3,Recruiting,TOP2A,1
Retinoblastoma,ETOPOSIDE,3,Terminated,TOP2A,1
Retinoblastoma,ETOPOSIDE,3,Unknown status,TOP2A,1
T-cell acute lymphoblastic leukemia,DOXORUBICIN,1,Completed,TOP2A,1
T-cell acute lymphoblastic leukemia,DOXORUBICIN,1,Recruiting,TOP2A,1
T-cell acute lymphoblastic leukemia,DOXORUBICIN,2,Completed,TOP2A,1
T-cell acute lymphoblastic leukemia,DOXORUBICIN,3,Unknown status,TOP2A,1
T-cell acute lymphoblastic leukemia,DOXORUBICIN,4,Completed,TOP2A,1
T-cell acute lymphoblastic leukemia,ETOPOSIDE,1,Completed,TOP2A,1
Thymic Carcinoma,AMRUBICIN,2,"Active, not recruiting",TOP2A,1
Thymic Carcinoma,DOXORUBICIN,1,Terminated,TOP2A,1
Thymoma,AMRUBICIN,2,"Active, not recruiting",TOP2A,1
Thymoma,DOXORUBICIN,1,Terminated,TOP2A,1
Thymoma,ETOPOSIDE,2,Completed,TOP2A,1
breast neoplasm,DOXORUBICIN,1,Recruiting,TOP2A,1
breast neoplasm,DOXORUBICIN,1,Terminated,TOP2A,1
breast neoplasm,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
leukemia,ETOPOSIDE PHOSPHATE,2,Unknown status,TOP2A,1
leukemia,DAUNORUBICIN,1,Unknown status,TOP2A,1
leukemia,DAUNORUBICIN,2,"Active, not recruiting",TOP2A,1
leukemia,DAUNORUBICIN,2,Terminated,TOP2A,1
leukemia,DAUNORUBICIN,3,Recruiting,TOP2A,1
leukemia,DAUNORUBICIN,3,Withdrawn,TOP2A,1
leukemia,DOXORUBICIN,1,Recruiting,TOP2A,1
B-cell acute lymphoblastic leukemia,DOXORUBICIN,2,Completed,TOP2A,1
leukemia,ETOPOSIDE,1,Terminated,TOP2A,1
leukemia,ETOPOSIDE,1,Unknown status,TOP2A,1
leukemia,ETOPOSIDE,3,Terminated,TOP2A,1
leukemia,ETOPOSIDE PHOSPHATE,1,Completed,TOP2A,1
leukemia,ETOPOSIDE PHOSPHATE,2,Recruiting,TOP2A,1
leukemia,IDARUBICIN,1,"Active, not recruiting",TOP2A,1
breast neoplasm,DOXORUBICIN,2,Recruiting,TOP2A,1
leukemia,IDARUBICIN,1,Recruiting,TOP2A,1
leukemia,IDARUBICIN,1,Withdrawn,TOP2A,1
leukemia,IDARUBICIN,3,"Active, not recruiting",TOP2A,1
leukemia,MITOXANTRONE,1,"Active, not recruiting",TOP2A,1
leukemia,MITOXANTRONE,1,Terminated,TOP2A,1
leukemia,MITOXANTRONE,2,Terminated,TOP2A,1
leukemia,TENIPOSIDE,2,Unknown status,TOP2A,1
leukemia,VOSAROXIN,1,"Active, not recruiting",TOP2A,1
lung adenocarcinoma,ETOPOSIDE,1,Terminated,TOP2A,1
lung adenocarcinoma,ETOPOSIDE,3,Completed,TOP2A,1
lung carcinoma,AMRUBICIN,3,"Active, not recruiting",TOP2A,1
lung carcinoma,BECATECARIN,2,Completed,TOP2A,1
leukemia,DAUNORUBICIN,1,Terminated,TOP2A,1
leukemia,AMSACRINE,3,Completed,TOP2A,1
leukemia,AMSACRINE,2,Recruiting,TOP2A,1
leukemia,AMSACRINE,1,Completed,TOP2A,1
head and neck malignant neoplasia,DOXORUBICIN,1,Completed,TOP2A,1
head and neck malignant neoplasia,DOXORUBICIN,1,Terminated,TOP2A,1
head and neck malignant neoplasia,DOXORUBICIN,2,Completed,TOP2A,1
hepatitis B infection,DAUNORUBICIN,3,Recruiting,TOP2A,1
hepatocellular carcinoma,ALDOXORUBICIN,1,Recruiting,TOP2A,1
hepatocellular carcinoma,DOXORUBICIN,1,Not yet recruiting,TOP2A,1
hepatocellular carcinoma,DOXORUBICIN,1,Recruiting,TOP2A,1
hepatocellular carcinoma,DOXORUBICIN,1,Terminated,TOP2A,1
hepatocellular carcinoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
hepatocellular carcinoma,DOXORUBICIN,2,Recruiting,TOP2A,1
hepatocellular carcinoma,DOXORUBICIN,2,Withdrawn,TOP2A,1
hepatocellular carcinoma,DOXORUBICIN,3,Withdrawn,TOP2A,1
hepatocellular carcinoma,ETOPOSIDE,2,Terminated,TOP2A,1
hepatocellular carcinoma,IDARUBICIN,1,Completed,TOP2A,1
hepatocellular carcinoma,IDARUBICIN,2,Completed,TOP2A,1
histiocytoma,DOXORUBICIN,3,Unknown status,TOP2A,1
histiocytoma,ETOPOSIDE,3,Completed,TOP2A,1
human herpesvirus 8 infection,DOXORUBICIN,2,Recruiting,TOP2A,1
inflammatory breast carcinoma,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
inflammatory breast carcinoma,DOXORUBICIN,2,Completed,TOP2A,1
inflammatory breast carcinoma,DOXORUBICIN,3,Terminated,TOP2A,1
kidney neoplasm,ETOPOSIDE,3,Not yet recruiting,TOP2A,1
large cell neuroendocrine carcinoma,ETOPOSIDE,2,Unknown status,TOP2A,1
leiomyosarcoma,DOXORUBICIN,1,Recruiting,TOP2A,1
leiomyosarcoma,DOXORUBICIN,3,Not yet recruiting,TOP2A,1
lung carcinoma,DOXORUBICIN,1,Completed,TOP2A,1
lung carcinoma,DOXORUBICIN,2,Terminated,TOP2A,1
lung carcinoma,ETOPOSIDE,1,Recruiting,TOP2A,1
lymphoid leukemia,MITOXANTRONE,2,Enrolling by invitation,TOP2A,1
lymphoid neoplasm,DAUNORUBICIN,1,Completed,TOP2A,1
lymphoid neoplasm,ETOPOSIDE,1,Withdrawn,TOP2A,1
lymphoma,BECATECARIN,1,Completed,TOP2A,1
lymphoma,DAUNORUBICIN,3,Terminated,TOP2A,1
lymphoma,DOXORUBICIN,1,Recruiting,TOP2A,1
lymphoma,DOXORUBICIN,1,Unknown status,TOP2A,1
lymphoma,DOXORUBICIN,3,Suspended,TOP2A,1
lymphoma,ETOPOSIDE,0,Terminated,TOP2A,1
lymphoma,ETOPOSIDE,1,Withdrawn,TOP2A,1
lymphoma,ETOPOSIDE,3,Recruiting,TOP2A,1
lymphoma,ETOPOSIDE PHOSPHATE,2,Recruiting,TOP2A,1
lymphoma,ETOPOSIDE PHOSPHATE,2,Unknown status,TOP2A,1
lymphoma,IDARUBICIN,1,Completed,TOP2A,1
lymphoma,IDARUBICIN,2,Terminated,TOP2A,1
lymphoma,MITOXANTRONE,1,Completed,TOP2A,1
lymphoma,MITOXANTRONE,2,"Active, not recruiting",TOP2A,1
lymphoma,MITOXANTRONE,2,Recruiting,TOP2A,1
lymphoma,MITOXANTRONE,2,Unknown status,TOP2A,1
lymphoma,MITOXANTRONE,2,Withdrawn,TOP2A,1
lymphoma,TENIPOSIDE,1,Completed,TOP2A,1
lymphoma,TENIPOSIDE,2,Completed,TOP2A,1
male breast carcinoma,BECATECARIN,2,Completed,TOP2A,1
male breast carcinoma,DOXORUBICIN,1,Terminated,TOP2A,1
male breast carcinoma,DOXORUBICIN,2,Completed,TOP2A,1
male breast carcinoma,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
lymphoid leukemia,MITOXANTRONE,2,Suspended,TOP2A,1
lymphoid leukemia,IDARUBICIN,2,Recruiting,TOP2A,1
lung carcinoma,ETOPOSIDE,1,Terminated,TOP2A,1
lymphoid leukemia,ETOPOSIDE PHOSPHATE,2,Completed,TOP2A,1
lung carcinoma,ETOPOSIDE,2,Recruiting,TOP2A,1
lung carcinoma,ETOPOSIDE,2,Withdrawn,TOP2A,1
lung carcinoma,ETOPOSIDE,3,Recruiting,TOP2A,1
lung carcinoma,ETOPOSIDE PHOSPHATE,1,Withdrawn,TOP2A,1
lung carcinoma,ETOPOSIDE PHOSPHATE,3,Completed,TOP2A,1
lung carcinoma,ETOPOSIDE PHOSPHATE,3,Unknown status,TOP2A,1
lymphoid leukemia,DAUNORUBICIN,2,"Active, not recruiting",TOP2A,1
lymphoid leukemia,DAUNORUBICIN,2,Completed,TOP2A,1
lymphoid leukemia,DAUNORUBICIN,2,Enrolling by invitation,TOP2A,1
lymphoid leukemia,DAUNORUBICIN,2,Recruiting,TOP2A,1
lymphoid leukemia,DAUNORUBICIN,2,Unknown status,TOP2A,1
lymphoid leukemia,DAUNORUBICIN,3,Completed,TOP2A,1
lymphoid leukemia,DAUNORUBICIN,4,Completed,TOP2A,1
lymphoid leukemia,DOXORUBICIN,1,Recruiting,TOP2A,1
lymphoid leukemia,DOXORUBICIN,1,Terminated,TOP2A,1
lymphoid leukemia,DOXORUBICIN,2,"Active, not recruiting",TOP2A,1
lymphoid leukemia,DOXORUBICIN,2,Unknown status,TOP2A,1
lymphoid leukemia,DOXORUBICIN,3,Completed,TOP2A,1
lymphoid leukemia,DOXORUBICIN,4,Completed,TOP2A,1
lymphoid leukemia,ETOPOSIDE,1,Recruiting,TOP2A,1
lymphoid leukemia,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
lymphoid leukemia,ETOPOSIDE,2,Enrolling by invitation,TOP2A,1
lymphoid leukemia,ETOPOSIDE,2,Terminated,TOP2A,1
lymphoid leukemia,ETOPOSIDE,2,Unknown status,TOP2A,1
lymphoid leukemia,ETOPOSIDE,4,Completed,TOP2A,1
gliosarcoma,ETOPOSIDE,2,Completed,TOP2A,1
gliosarcoma,ETOPOSIDE,1,Recruiting,TOP2A,1
gliosarcoma,ETOPOSIDE,1,Completed,TOP2A,1
cervical carcinoma,DOXORUBICIN,2,Recruiting,TOP2A,1
childhood B acute lymphoblastic leukemia,DAUNORUBICIN,1,Completed,TOP2A,1
childhood B acute lymphoblastic leukemia,DAUNORUBICIN,2,Suspended,TOP2A,1
childhood B acute lymphoblastic leukemia,DOXORUBICIN,2,Completed,TOP2A,1
childhood B acute lymphoblastic leukemia,ETOPOSIDE,2,Terminated,TOP2A,1
childhood B acute lymphoblastic leukemia,ETOPOSIDE,3,Completed,TOP2A,1
childhood B acute lymphoblastic leukemia,ETOPOSIDE PHOSPHATE,2,Completed,TOP2A,1
childhood B acute lymphoblastic leukemia,IDARUBICIN,4,Unknown status,TOP2A,1
childhood T acute lymphoblastic leukemia,DAUNORUBICIN,1,Completed,TOP2A,1
childhood T acute lymphoblastic leukemia,DAUNORUBICIN,3,Completed,TOP2A,1
childhood T acute lymphoblastic leukemia,DAUNORUBICIN,3,Suspended,TOP2A,1
childhood T acute lymphoblastic leukemia,DOXORUBICIN,2,Completed,TOP2A,1
childhood T acute lymphoblastic leukemia,DOXORUBICIN,3,Suspended,TOP2A,1
childhood T acute lymphoblastic leukemia,ETOPOSIDE,3,Completed,TOP2A,1
childhood T acute lymphoblastic leukemia,ETOPOSIDE,3,Suspended,TOP2A,1
childhood T acute lymphoblastic leukemia,ETOPOSIDE PHOSPHATE,2,Completed,TOP2A,1
childhood acute myeloid leukemia,DAUNORUBICIN,1,Completed,TOP2A,1
childhood acute myeloid leukemia,DAUNORUBICIN,3,Completed,TOP2A,1
childhood acute myeloid leukemia,ETOPOSIDE,2,Completed,TOP2A,1
childhood acute myeloid leukemia,ETOPOSIDE,3,Completed,TOP2A,1
childhood acute myeloid leukemia,IDARUBICIN,3,Completed,TOP2A,1
childhood acute myeloid leukemia,MITOXANTRONE,3,Completed,TOP2A,1
childhood acute myeloid leukemia with maturation,DAUNORUBICIN,3,Completed,TOP2A,1
childhood acute myeloid leukemia with maturation,ETOPOSIDE,3,Completed,TOP2A,1
childhood supratentorial ependymoma,ETOPOSIDE,3,Recruiting,TOP2A,1
cholangiocarcinoma,DOXORUBICIN,2,Recruiting,TOP2A,1
cervical carcinoma,DOXORUBICIN,2,Terminated,TOP2A,1
central nervous system cancer,MITOXANTRONE,1,Recruiting,TOP2A,1
choroid plexus cancer,ETOPOSIDE,3,Completed,TOP2A,1
central nervous system cancer,ETOPOSIDE PHOSPHATE,3,Completed,TOP2A,1
breast neoplasm,DOXORUBICIN,2,Unknown status,TOP2A,1
breast neoplasm,DOXORUBICIN,3,"Active, not recruiting",TOP2A,1
breast neoplasm,DOXORUBICIN,3,Recruiting,TOP2A,1
breast neoplasm,DOXORUBICIN,4,Completed,TOP2A,1
cancer,DOXORUBICIN,1,Recruiting,TOP2A,1
cancer,DOXORUBICIN,1,Terminated,TOP2A,1
cancer,DOXORUBICIN,1,Withdrawn,TOP2A,1
cancer,ETOPOSIDE,1,"Active, not recruiting",TOP2A,1
cancer,ETOPOSIDE,1,Suspended,TOP2A,1
cancer,ETOPOSIDE,2,Recruiting,TOP2A,1
carcinoma,BERUBICIN,1,Terminated,TOP2A,1
carcinoma,DOXORUBICIN,1,Completed,TOP2A,1
carcinoma,DOXORUBICIN,2,Completed,TOP2A,1
carcinoma,DOXORUBICIN,2,Unknown status,TOP2A,1
carcinoma,DOXORUBICIN,3,Completed,TOP2A,1
carcinoma,DOXORUBICIN,3,Unknown status,TOP2A,1
carcinoma,ETOPOSIDE,2,Completed,TOP2A,1
carcinoma,ETOPOSIDE,3,Completed,TOP2A,1
carcinoma,ETOPOSIDE,3,Unknown status,TOP2A,1
carcinoma,ETOPOSIDE PHOSPHATE,3,Recruiting,TOP2A,1
central nervous system cancer,BERUBICIN,1,Completed,TOP2A,1
central nervous system cancer,DOXORUBICIN,1,Completed,TOP2A,1
central nervous system cancer,DOXORUBICIN,2,Completed,TOP2A,1
central nervous system cancer,ETOPOSIDE,3,Completed,TOP2A,1
central nervous system cancer,ETOPOSIDE PHOSPHATE,2,Recruiting,TOP2A,1
choroid plexus cancer,DOXORUBICIN,3,Suspended,TOP2A,1
choroid plexus cancer,ETOPOSIDE,3,Suspended,TOP2A,1
glioma,ETOPOSIDE,2,Completed,TOP2A,1
diffuse large B-cell lymphoma,ETOPOSIDE,3,Suspended,TOP2A,1
diffuse large B-cell lymphoma,ETOPOSIDE,3,Unknown status,TOP2A,1
diffuse large B-cell lymphoma,ETOPOSIDE PHOSPHATE,3,Recruiting,TOP2A,1
diffuse large B-cell lymphoma,MITOXANTRONE,2,Terminated,TOP2A,1
diffuse large B-cell lymphoma,MITOXANTRONE,3,Unknown status,TOP2A,1
ductal adenocarcinoma,DOXORUBICIN,2,Terminated,TOP2A,1
embryonal rhabdomyosarcoma,DOXORUBICIN,2,Completed,TOP2A,1
embryonal rhabdomyosarcoma,ETOPOSIDE,2,Completed,TOP2A,1
endometrial neoplasm,DOXORUBICIN,2,Terminated,TOP2A,1
endometrial neoplasm,DOXORUBICIN,2,Unknown status,TOP2A,1
endometrial neoplasm,DOXORUBICIN,2,Withdrawn,TOP2A,1
endometrial neoplasm,DOXORUBICIN,3,Recruiting,TOP2A,1
ependymoma,ETOPOSIDE,1,Recruiting,TOP2A,1
ependymoma,ETOPOSIDE,2,Recruiting,TOP2A,1
ependymoma,ETOPOSIDE,2,Terminated,TOP2A,1
esophageal carcinoma,DOXORUBICIN,2,Unknown status,TOP2A,1
gastric carcinoma,DOXORUBICIN,2,Unknown status,TOP2A,1
gastric carcinoma,ETOPOSIDE,2,Not yet recruiting,TOP2A,1
gastric carcinoma,ETOPOSIDE,3,Unknown status,TOP2A,1
germ cell tumor,ETOPOSIDE,2,Recruiting,TOP2A,1
germ cell tumor,ETOPOSIDE,2,Unknown status,TOP2A,1
germ cell tumor,ETOPOSIDE,3,Recruiting,TOP2A,1
germ cell tumor,ETOPOSIDE,4,Unknown status,TOP2A,1
glioblastoma multiforme,ALDOXORUBICIN,2,Completed,TOP2A,1
glioblastoma multiforme,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
glioblastoma multiforme,DOXORUBICIN,1,Completed,TOP2A,1
diffuse large B-cell lymphoma,ETOPOSIDE,3,Terminated,TOP2A,1
diffuse large B-cell lymphoma,ETOPOSIDE,2,Not yet recruiting,TOP2A,1
chronic lymphocytic leukemia,DOXORUBICIN,2,Completed,TOP2A,1
diffuse large B-cell lymphoma,ETOPOSIDE,2,Enrolling by invitation,TOP2A,1
chronic lymphocytic leukemia,DOXORUBICIN,3,Completed,TOP2A,1
chronic lymphocytic leukemia,MITOXANTRONE,3,Terminated,TOP2A,1
chronic myelogenous leukemia,DAUNORUBICIN,1,Terminated,TOP2A,1
chronic myelogenous leukemia,ETOPOSIDE,1,Completed,TOP2A,1
chronic myelogenous leukemia,IDARUBICIN,2,Completed,TOP2A,1
chronic myelogenous leukemia,IDARUBICIN,2,Terminated,TOP2A,1
chronic myelogenous leukemia,MITOXANTRONE,1,Completed,TOP2A,1
chronic myelogenous leukemia,VOSAROXIN,1,Completed,TOP2A,1
chronic myeloproliferative disorder,ETOPOSIDE,1,Completed,TOP2A,1
chronic myeloproliferative disorder,ETOPOSIDE,2,"Active, not recruiting",TOP2A,1
chronic myeloproliferative disorder,IDARUBICIN,2,Completed,TOP2A,1
colorectal cancer,ETOPOSIDE,2,Recruiting,TOP2A,1
colorectal cancer,ETOPOSIDE,3,Recruiting,TOP2A,1
colorectal carcinoma,BECATECARIN,2,Completed,TOP2A,1
colorectal carcinoma,DOXORUBICIN,1,Completed,TOP2A,1
core binding factor acute myeloid leukemia,DAUNORUBICIN,2,"Active, not recruiting",TOP2A,1
diffuse large B-cell lymphoma,DOXORUBICIN,1,"Active, not recruiting",TOP2A,1
diffuse large B-cell lymphoma,DOXORUBICIN,1,Not yet recruiting,TOP2A,1
diffuse large B-cell lymphoma,DOXORUBICIN,1,Suspended,TOP2A,1
diffuse large B-cell lymphoma,DOXORUBICIN,2,Enrolling by invitation,TOP2A,1
diffuse large B-cell lymphoma,DOXORUBICIN,2,Not yet recruiting,TOP2A,1
diffuse large B-cell lymphoma,DOXORUBICIN,2,Withdrawn,TOP2A,1
diffuse large B-cell lymphoma,DOXORUBICIN,3,Withdrawn,TOP2A,1
diffuse large B-cell lymphoma,DOXORUBICIN,4,Recruiting,TOP2A,1
diffuse large B-cell lymphoma,DOXORUBICIN,4,Unknown status,TOP2A,1
uterine sarcoma,DOXORUBICIN,3,Unknown status,TOP2A,1
